AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Polycystic Ovary SyndromeHyperandrogenismHirsutismOvaryOligomenorrheaMetforminAnovulationClomiphenePolycystic Kidney DiseasesInsulin ResistanceTestosteroneAndrogensInfertility, FemaleFertility Agents, FemaleSyndrome17-alpha-HydroxyprogesteroneAndrostenedioneMenstruation DisturbancesPolycystic Kidney, Autosomal DominantLuteinizing HormoneDehydroepiandrosterone SulfateOvulation InductionCyproterone AcetateSex Hormone-Binding GlobulinAcne VulgarisFollicle Stimulating HormoneAnti-Mullerian HormoneHypoglycemic AgentsInsulinOvulationBody Mass IndexObesityMenstrual CycleCase-Control StudiesPregnancyAmenorrheaBlood GlucoseElectrocoagulationGlucose Tolerance TestHyperinsulinismEthinyl EstradiolHormonesOvarian FollicleMetabolic Syndrome XGonadotropinsDiathermyPregnancy RateMenstruationSteroid 17-alpha-HydroxylaseVirilismDehydroepiandrosteroneFollicle Stimulating Hormone, HumanTRPP Cation ChannelsPolycystic Kidney, Autosomal RecessiveGonadal Steroid HormonesLive BirthMenstruation-Inducing AgentsTheca CellsOvarian Hyperstimulation SyndromeEstradiolFertilization in VitroOvarian DiseasesAcanthosis NigricansReproductive Techniques, AssistedAdrenarcheFollicular FluidSteroidsThiazolidinedionesGonadotropin-Releasing HormoneTestosterone PropionateInfertilityFollistatinElectroacupunctureGlucose IntoleranceReceptors, FSHPhenotypeWaist-Hip RatioBiological MarkersRisk FactorsPrevalenceOverweightProgesteroneDiabetes, GestationalGlucose Metabolism DisordersProspective StudiesAndrogen AntagonistsGenotypeAdiponectinThinnessEndocrine System DiseasesAlopeciaNational Institute of Child Health and Human Development (U.S.)CystsHair RemovalFollicular PhaseContraceptives, Oral, CombinedContraceptive AgentsPolymorphism, Single NucleotideChorionic GonadotropinPregnancy OutcomeInhibinsGranulosa CellsCohort StudiesGene FrequencyBody ConstitutionCross-Sectional StudiesAbdominal FatDown SyndromeGlucose Clamp TechniqueHormones, EctopicPolymorphism, GeneticTreatment OutcomeGenetic Predisposition to DiseaseLipidsReference Values
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.Ovary: The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.Oligomenorrhea: Abnormally infrequent menstruation.Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)Anovulation: Suspension or cessation of OVULATION in animals or humans with follicle-containing ovaries (OVARIAN FOLLICLE). Depending on the etiology, OVULATION may be induced with appropriate therapy.Clomiphene: A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. Note that ENCLOMIPHENE and ZUCLOMIPHENE are the (E) and (Z) isomers of Clomiphene respectively.Polycystic Kidney Diseases: Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.Testosterone: A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.Androgens: Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.Infertility, Female: Diminished or absent ability of a female to achieve conception.Fertility Agents, Female: Compounds which increase the capacity to conceive in females.Syndrome: A characteristic symptom complex.17-alpha-Hydroxyprogesterone: A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. It serves as an intermediate in the biosynthesis of HYDROCORTISONE and GONADAL STEROID HORMONES.Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.Menstruation Disturbances: Variations of menstruation which may be indicative of disease.Polycystic Kidney, Autosomal Dominant: Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.Luteinizing Hormone: A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.Ovulation Induction: Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum.Cyproterone Acetate: An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.Sex Hormone-Binding Globulin: A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Sex hormone-binding protein has the same amino acid sequence as ANDROGEN-BINDING PROTEIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications.Acne Vulgaris: A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.Follicle Stimulating Hormone: A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.Anti-Mullerian Hormone: A glycoprotein that causes regression of MULLERIAN DUCTS. It is produced by SERTOLI CELLS of the TESTES. In the absence of this hormone, the Mullerian ducts develop into structures of the female reproductive tract. In males, defects of this hormone result in persistent Mullerian duct, a form of MALE PSEUDOHERMAPHRODITISM.Hypoglycemic Agents: Substances which lower blood glucose levels.Insulin: A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).Ovulation: The discharge of an OVUM from a rupturing follicle in the OVARY.Body Mass Index: An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)Obesity: A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).Menstrual Cycle: The period from onset of one menstrual bleeding (MENSTRUATION) to the next in an ovulating woman or female primate. The menstrual cycle is regulated by endocrine interactions of the HYPOTHALAMUS; the PITUITARY GLAND; the ovaries; and the genital tract. The menstrual cycle is divided by OVULATION into two phases. Based on the endocrine status of the OVARY, there is a FOLLICULAR PHASE and a LUTEAL PHASE. Based on the response in the ENDOMETRIUM, the menstrual cycle is divided into a proliferative and a secretory phase.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Amenorrhea: Absence of menstruation.Blood Glucose: Glucose in blood.Electrocoagulation: Procedures using an electrically heated wire or scalpel to treat hemorrhage (e.g., bleeding ulcers) and to ablate tumors, mucosal lesions, and refractory arrhythmias. It is different from ELECTROSURGERY which is used more for cutting tissue than destroying and in which the patient is part of the electric circuit.Glucose Tolerance Test: A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg).Hyperinsulinism: A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.Hormones: Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.Ovarian Follicle: An OOCYTE-containing structure in the cortex of the OVARY. The oocyte is enclosed by a layer of GRANULOSA CELLS providing a nourishing microenvironment (FOLLICULAR FLUID). The number and size of follicles vary depending on the age and reproductive state of the female. The growing follicles are divided into five stages: primary, secondary, tertiary, Graafian, and atretic. Follicular growth and steroidogenesis depend on the presence of GONADOTROPINS.Metabolic Syndrome X: A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)Gonadotropins: Hormones that stimulate gonadal functions such as GAMETOGENESIS and sex steroid hormone production in the OVARY and the TESTIS. Major gonadotropins are glycoproteins produced primarily by the adenohypophysis (GONADOTROPINS, PITUITARY) and the placenta (CHORIONIC GONADOTROPIN). In some species, pituitary PROLACTIN and PLACENTAL LACTOGEN exert some luteotropic activities.Diathermy: The induction of local hyperthermia by either short radio waves or high-frequency sound waves.Pregnancy Rate: The ratio of the number of conceptions (CONCEPTION) including LIVE BIRTH; STILLBIRTH; and fetal losses, to the mean number of females of reproductive age in a population during a set time period.Menstruation: The periodic shedding of the ENDOMETRIUM and associated menstrual bleeding in the MENSTRUAL CYCLE of humans and primates. Menstruation is due to the decline in circulating PROGESTERONE, and occurs at the late LUTEAL PHASE when LUTEOLYSIS of the CORPUS LUTEUM takes place.Steroid 17-alpha-Hydroxylase: A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation.Virilism: Development of male secondary SEX CHARACTERISTICS in the FEMALE. It is due to the effects of androgenic metabolites of precursors from endogenous or exogenous sources, such as ADRENAL GLANDS or therapeutic drugs.Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.Follicle Stimulating Hormone, Human: A major gonadotropin secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and the LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. The alpha subunit is common in the three human pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.TRPP Cation Channels: A subgroup of TRP cation channels that are widely expressed in various cell types. Defects are associated with POLYCYSTIC KIDNEY DISEASES.Polycystic Kidney, Autosomal Recessive: A genetic disorder with autosomal recessive inheritance, characterized by multiple CYSTS in both KIDNEYS and associated LIVER lesions. Serious manifestations are usually present at BIRTH with high PERINATAL MORTALITY.Gonadal Steroid Hormones: Steroid hormones produced by the GONADS. They stimulate reproductive organs, germ cell maturation, and the secondary sex characteristics in the males and the females. The major sex steroid hormones include ESTRADIOL; PROGESTERONE; and TESTOSTERONE.Live Birth: The event that a FETUS is born alive with heartbeats or RESPIRATION regardless of GESTATIONAL AGE. Such liveborn is called a newborn infant (INFANT, NEWBORN).Menstruation-Inducing Agents: Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhea is a secondary result. (From Dorland, 27th ed)Theca Cells: The flattened stroma cells forming a sheath or theca outside the basal lamina lining the mature OVARIAN FOLLICLE. Thecal interstitial or stromal cells are steroidogenic, and produce primarily ANDROGENS which serve as precusors of ESTROGENS in the GRANULOSA CELLS.Ovarian Hyperstimulation Syndrome: A complication of OVULATION INDUCTION in infertility treatment. It is graded by the severity of symptoms which include OVARY enlargement, multiple OVARIAN FOLLICLES; OVARIAN CYSTS; ASCITES; and generalized EDEMA. The full-blown syndrome may lead to RENAL FAILURE, respiratory distress, and even DEATH. Increased capillary permeability is caused by the vasoactive substances, such as VASCULAR ENDOTHELIAL GROWTH FACTORS, secreted by the overly-stimulated OVARIES.Estradiol: The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.Fertilization in Vitro: An assisted reproductive technique that includes the direct handling and manipulation of oocytes and sperm to achieve fertilization in vitro.Ovarian Diseases: Pathological processes of the OVARY.Acanthosis Nigricans: A circumscribed melanosis consisting of a brown-pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds. It occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder.Reproductive Techniques, Assisted: Clinical and laboratory techniques used to enhance fertility in humans and animals.Adrenarche: A stage of development at which the ADRENAL GLANDS undergo maturation leading to the capability of producing increasing amounts of adrenal androgens, DEHYDROEPIANDROSTERONE and ANDROSTENEDIONE. Adrenarche usually begins at about 7 or 8 years of age before the signs of PUBERTY and continues throughout puberty.Follicular Fluid: The fluid surrounding the OVUM and GRANULOSA CELLS in the Graafian follicle (OVARIAN FOLLICLE). The follicular fluid contains sex steroids, glycoprotein hormones, plasma proteins, mucopolysaccharides, and enzymes.Steroids: A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)Thiazolidinediones: THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).Gonadotropin-Releasing Hormone: A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.Testosterone Propionate: An ester of TESTOSTERONE with a propionate substitution at the 17-beta position.Infertility: Inability to reproduce after a specified period of unprotected intercourse. Reproductive sterility is permanent infertility.Follistatin: A broadly distributed protein that binds directly to ACTIVINS. It functions as an activin antagonist, inhibits FOLLICLE STIMULATING HORMONE secretion, regulates CELL DIFFERENTIATION, and plays an important role in embryogenesis. Follistatin is a single glycosylated polypeptide chain of approximately 37-kDa and is not a member of the inhibin family (INHIBINS). Follistatin also binds and neutralizes many members of the TRANSFORMING GROWTH FACTOR BETA family.Electroacupuncture: A form of acupuncture with electrical impulses passing through the needles to stimulate NERVE TISSUE. It can be used for ANALGESIA; ANESTHESIA; REHABILITATION; and treatment for diseases.Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.Receptors, FSH: Cell surface proteins that bind FOLLICLE STIMULATING HORMONE with high affinity and trigger intracellular changes influencing the behavior of cells.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Waist-Hip Ratio: The waist circumference measurement divided by the hip circumference measurement. For both men and women, a waist-to-hip ratio (WHR) of 1.0 or higher is considered "at risk" for undesirable health consequences, such as heart disease and ailments associated with OVERWEIGHT. A healthy WHR is 0.90 or less for men, and 0.80 or less for women. (National Center for Chronic Disease Prevention and Health Promotion, 2004)Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.Overweight: A status with BODY WEIGHT that is above certain standard of acceptable or desirable weight. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal "over fat".Progesterone: The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.Diabetes, Gestational: Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.Glucose Metabolism Disorders: Pathological conditions in which the BLOOD GLUCOSE cannot be maintained within the normal range, such as in HYPOGLYCEMIA and HYPERGLYCEMIA. Etiology of these disorders varies. Plasma glucose concentration is critical to survival for it is the predominant fuel for the CENTRAL NERVOUS SYSTEM.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Androgen Antagonists: Compounds which inhibit or antagonize the biosynthesis or actions of androgens.Genotype: The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.Adiponectin: A 30-kDa COMPLEMENT C1Q-related protein, the most abundant gene product secreted by FAT CELLS of the white ADIPOSE TISSUE. Adiponectin modulates several physiological processes, such as metabolism of GLUCOSE and FATTY ACIDS, and immune responses. Decreased plasma adiponectin levels are associated with INSULIN RESISTANCE; TYPE 2 DIABETES MELLITUS; OBESITY; and ATHEROSCLEROSIS.Thinness: A state of insufficient flesh on the body usually defined as having a body weight less than skeletal and physical standards. Depending on age, sex, and genetic background, a BODY MASS INDEX of less than 18.5 is considered as underweight.Endocrine System Diseases: Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES.Alopecia: Absence of hair from areas where it is normally present.National Institute of Child Health and Human Development (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. It was initially established to investigate the broad aspects of human development as a means of understanding developmental disabilities, including mental retardation, and the events that occur during pregnancy. It now conducts and supports research on all stages of human development. It was established in 1962.Cysts: Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.Hair Removal: Methods used to remove unwanted facial and body hair.Follicular Phase: The period of the MENSTRUAL CYCLE representing follicular growth, increase in ovarian estrogen (ESTROGENS) production, and epithelial proliferation of the ENDOMETRIUM. Follicular phase begins with the onset of MENSTRUATION and ends with OVULATION.Contraceptives, Oral, Combined: Fixed drug combinations administered orally for contraceptive purposes.Contraceptive Agents: Chemical substances that prevent or reduce the probability of CONCEPTION.Polymorphism, Single Nucleotide: A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.Chorionic Gonadotropin: A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN).Pregnancy Outcome: Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; SPONTANEOUS ABORTION; INDUCED ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.Inhibins: Glycoproteins that inhibit pituitary FOLLICLE STIMULATING HORMONE secretion. Inhibins are secreted by the Sertoli cells of the testes, the granulosa cells of the ovarian follicles, the placenta, and other tissues. Inhibins and ACTIVINS are modulators of FOLLICLE STIMULATING HORMONE secretions; both groups belong to the TGF-beta superfamily, as the TRANSFORMING GROWTH FACTOR BETA. Inhibins consist of a disulfide-linked heterodimer with a unique alpha linked to either a beta A or a beta B subunit to form inhibin A or inhibin B, respectivelyGranulosa Cells: Supporting cells for the developing female gamete in the OVARY. They are derived from the coelomic epithelial cells of the gonadal ridge. Granulosa cells form a single layer around the OOCYTE in the primordial ovarian follicle and advance to form a multilayered cumulus oophorus surrounding the OVUM in the Graafian follicle. The major functions of granulosa cells include the production of steroids and LH receptors (RECEPTORS, LH).Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Gene Frequency: The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION.Body Constitution: The physical characteristics of the body, including the mode of performance of functions, the activity of metabolic processes, the manner and degree of reactions to stimuli, and power of resistance to the attack of pathogenic organisms.Cross-Sectional Studies: Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.Abdominal Fat: Fatty tissue in the region of the ABDOMEN. It includes the ABDOMINAL SUBCUTANEOUS FAT and the INTRA-ABDOMINAL FAT.Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)Glucose Clamp Technique: Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.Hormones, Ectopic: Hormones released from neoplasms or from other cells that are not the usual sources of hormones.Polymorphism, Genetic: The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Genetic Predisposition to Disease: A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.Lipids: A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)Reference Values: The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.

The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. (1/1493)

OBJECTIVE: To determine whether metformin. when given to non-diabetic women with polycystic ovary syndrome (PCOS), results in a reduction of insulin resistance and hyperinsulinemia while body weight is maintained. Also we aimed to see whether the reduction in insulin levels attenuates the activity of adrenal P450c17alpha enzyme in patients with PCOS. DESIGN: We investigated the 17-hydroxyprogesterone (17-OHP) and androstenedione responses to ACTH, insulin responses to an oral glucose tolerance test (OGTT) and glucose disposal rate in an insulin tolerance test before and after metformin therapy (500 mg, orally, twice daily, for 12 weeks). METHODS: The presence of hyperinsulinemia in 15 women with PCOS was demonstrated by an OGTT and results were compared with those of 10 healthy women. Insulin sensitivity was measured by the rate of endogenous glucose disposal after i.v. bolus injection of insulin. 17-OHP and androstenedione responses to ACTH were measured in all the women with PCOS and the normal women. RESULTS: Women with PCOS were hyperinsulinemic (102.0+/-13.0 (S.E.M.) VS 46.2+/-4.4 pmol/l) and hyperandrogenemic (free testosterone 15.3+/-1.7 vs 7.9+/-0.6 nmol/l; androstenedione 11.8+/-0.8 vs 8.2+/-0.6 nmol/l) and more hirsute (modified Ferriman-Gallwey score, 17.7+/-1.6 vs 3.0+/-0.3) than healthy women. In addition, women with PCOS had higher 17-OHP and androstenedione responses to ACTH when compared with healthy women. Metformin therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels. But 17-OHP and androstenedione responses to ACTH were unaltered in response to metformin. CONCLUSIONS: PCOS is characterized by hyperactivity of the adrenal P450c17alpha enzyme and insulin resistance. It seems that there is no direct relationship between insulin resistance and adrenal P450c17alpha enzyme dysregulation.  (+info)

No association between the -308 polymorphism in the tumour necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries. (2/1493)

The tumour necrosis factor (TNF)2 allele appears to be linked with increased insulin resistance and obesity, conditions often found in overweight patients with polycystic ovary syndrome (PCOS). The significance of TNFalpha polymorphism in relation to the clinical and biochemical parameters associated with PCOS was investigated in 122 well-characterized patients with polycystic ovaries (PCO). Of these, 84 had an abnormal menstrual cycle and were classified as having PCOS, while the remaining 38 had a normal menstrual cycle and were classified as having PCO. There were a further 28 individuals without PCO (non-PCO) and 108 individuals whose PCO status was undetermined (reference population). The promoter region of the TNFalpha gene was amplified by polymerase chain reaction (PCR), and the presence or absence of the polymorphism at -308 was determined by single-strand conformational polymorphism (SSCP) analysis. The less common TNF allele (TNF2) was found as TNF1/2 or TNF2/2 in 11/38 (29%) of PCO subjects, 25/84 (30%) of PCOS subjects, 7/28 (25%) of non-PCO subjects, and 45/108 (42%) of the reference population. There was no significant difference in the incidence of the TNF2 allele between the groups. The relationship of TNF genotype to clinical and biochemical parameters was examined. In both the PCO group and the PCOS group, the presence of the TNF2 allele was significantly associated with lower glucose values obtained from the glucose tolerance testing (P<0.05). The TNF genotype was not significantly associated with any clinical or biochemical parameter measured in the PCO, PCOS or non-PCOS groups. Thus, the TNFalpha -308 polymorphism does not appear to strongly influence genetic susceptibility to polycystic ovaries.  (+info)

The mechanism of action of epidermal growth factor and transforming growth factor alpha on aromatase activity in granulosa cells from polycystic ovaries. (3/1493)

We investigated aromatization and the mechanism of action of epidermal growth factor (EGF) and transforming growth factor alpha (TGFalpha) on oestradiol biosynthesis in freshly prepared granulosa cells from polycystic ovaries. Freshly prepared granulosa cells from polycystic ovaries incubated for only 3 h under basal conditions secreted significantly (P< 0.001) greater amounts of oestradiol-17beta than that of granulosa cells from normal ovaries. 8-Bromo-cyclic adenosine monophosphate (8-Br-cAMP), but not follicle stimulating hormone (FSH) or luteinizing hormone (LH), further enhanced this activity. Both EGF and TGFalpha inhibited gonadotrophinor 8-Br-cAMP-stimulated, but not basal, oestradiol production. LH receptor (LHR) binding, estimated by immunolabelling the bound LH, was significantly (P< 0.001) reduced in granulosa cells from polycystic ovaries when compared with cells from normal ovaries. EGF or TGFalpha significantly reduced the binding in cultured cells from all patient groups (P< 0.05). More interestingly, a further increase of the inhibitory effect was seen in granulosa cells from polycystic ovaries (P < 0.001). In conclusion, granulosa cells from polycystic ovaries contain high levels of basal aromatase activity in vitro, which is probably inherited from the in-vivo condition. EGF and TGFalpha suppress oestradiol synthesis at a step beyond the production of cAMP and also LHR binding with more effect in granulosa cells from polycystic ovaries.  (+info)

Retrieval, maturation, and fertilization of immature oocytes obtained from unstimulated patients with polycystic ovary syndrome. (4/1493)

PURPOSE: Our purpose was to determine whether immature oocytes could be retrieved under local anesthesia, whether these oocytes would mature and fertilize in vitro, and whether adequate endometrium development could be obtained after hormonal supplementation. METHODS: Ovum pick-up was performed under local anesthesia. Immature oocytes were cultured and inseminated. To prepare the endometrium, estradiolvalerate was administered in combination with micronized progesterone. RESULTS: Immature oocytes were obtained in all cases. Fifty-six percent (n = 30) of the oocytes developed into metaphase II (MII) after 48 hr of culture, and another 20% reached the MII stage by 72 hr. Normal fertilization was observed in only 10% of oocytes inseminated. No embryonic development occurred, and therefore embryo transfer was not performed in any of the patients. Endometrial microbiopsy was performed in all subjects and endometrial development was considered sufficient in eight patients. CONCLUSIONS: We collected immature oocytes from patients with polycystic ovary syndrome without general anesthesia. In vitro maturation of these oocytes seemed adequate but fertilization rates were poor. Sufficient endometrial quality was obtained after hormonal substitution.  (+info)

Insulin in obstetrics: a main parameter in the management of pregnancy. (5/1493)

Insulin plays a central role in human pregnancy. Maternal insulin sensitivity decreases with advancing gestation in order to provide glucose and possibly other nutrients for feto-placental growth and energy needs. Moreover, alterations of insulin metabolism are clearly involved in the development of gestational diabetes. In recent years, hyperinsulinaemia has been also proposed as a possible pathogenic factor in the development of gestational hypertension and preeclampsia; furthermore it has also been postulated that there is an involvement of insulin sensitivity in fetal growth restriction. These intriguing data have stimulated our interest in summarizing the physiopathological mechanisms by which the pancreatic hormone could be involved in obstetrics.  (+info)

The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. (6/1493)

Adrenal hyperandrogenism is prevalent in many women with polycystic ovary syndrome (PCOS), although the expression of this enhanced secretion may be heterogeneous. Since no single factor acts in isolation, this study was performed to assess the influence of oestradiol (total and unbound), insulin, insulin-like growth factor (IGF)-I, IGF-II and the binding proteins IGFBP-I, and IGFBP-3, on basal and adrenocorticotrophic hormone (ACTH) stimulated adrenal androgen secretion in 25 women with PCOS and 10 matched ovulatory controls. Women with PCOS exhibited elevations of all androgens as well as unbound oestradiol, insulin and non-IGFBP-1 bound IGF-I. Positive correlations were noted between oestrogen and basal and ACTH stimulated delta 5 adrenal androgens. Serum IGF-I was only correlated with basal dehydroepiandrosterone sulphate (DHEA-S), while insulin exhibited a strong correlation with the delta 4 pathway and androstenedione formation in particular. This correlation was also confirmed by dividing the PCOS group into those women with and without hyperinsulinaemia. The activity of 17,20 lyase favouring androstenedione was increased in the hyperinsulinaemic women. By multivariate analyses, body mass index did not influence these findings. Although there are inherent difficulties in making major conclusions based on correlative analyses, it is suggested that oestrogen may have a greater influence on enhancing delta 5 adrenal androgen secretion, and insulin a greater effect on the delta 4 pathway. In turn, the relative importance of these influences may contribute to the heterogeneous nature of adrenal hyperandrogenism in PCOS.  (+info)

Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. (7/1493)

Patients with polycystic ovarian syndrome (PCOS) have higher miscarriage rates. It is postulated that this is caused by a lower rate of mature oocytes, and a lower quality of embryos. Retrospectively we analysed 51 intracytoplasmic sperm injection (ICSI) cycles of 31 PCOS patients. These data were compared to age-matched controls (105 cycles) during the same period. All patients of both groups received gonadotrophin-releasing hormone (GnRH) agonists prior to gonadotrophin treatment. The rate of metaphase II oocytes (MII) was not different. However, the mean absolute number of normally fertilized oocytes was significantly higher in PCOS patients (5.00 versus 3.56, P < 0.01), due to a higher number of oocytes retrieved. More embryos were transferred by cycle in the PCOS group (2.69 versus 2.17, P < 0.05), with a higher cumulative embryo score. The overall and multiple pregnancy rate showed no differences and the clinical abortion rate was lower (21 versus 41.67%, P < 0.05) in the controls. Our findings demonstrate that negative factors unconnected to oocyte morphology must be present in PCOS patients. It is possible that only cytoplasmic, not nuclear, maturity is influenced in these patients.  (+info)

The pattern of changes in ovarian stromal and uterine artery blood flow velocities during in vitro fertilization treatment and its relationship with outcome of the cycle. (8/1493)

OBJECTIVES: To assess the effect of short-term (2-3 weeks) pituitary suppression and controlled ovarian stimulation on ovarian and uterine artery Doppler measurements during the in vitro fertilization (IVF) treatment cycle and to compare the pattern of these changes between conception and non-conception cycles as well as between patients with normal and those with polycystic ovaries. DESIGN: Prospective observational study of women undergoing IVF treatment. SUBJECTS: Women using the long-treatment buserelin protocol who did not have uterine fibroids, ovarian cysts or endometrioma. METHODS: Serial transvaginal color and pulsed Doppler measurements of ovarian stromal and uterine artery blood flow velocity were carried out in the early follicular phase of the menstrual cycle, on the day of pituitary suppression and on the day of administration of human chorionic gonadotropin (hCG). The main outcome measures were the ovarian stromal and uterine artery blood flow peak systolic velocity (PSV) and pulsatility index (PI). RESULTS: A total of 105 patients were recruited but six patients were excluded from the analysis because they had only one stage of the measurements performed. There was a significant decline in mean ovarian stromal artery PSV after 2-3 weeks of gonadotropin releasing hormone (GnRH) agonist therapy but no effect on ovarian stromal artery PI. The mean uterine artery PSV or PI did not change significantly after 2-3 weeks of GnRH agonist therapy. There was a significantly higher mean ovarian stromal artery PSV in conception cycles compared to non-conception cycles in the early follicular phase and on the day of pituitary suppression, but not on the day of hCG administration. There were no differences between conception and non-conception cycles in the mean uterine artery PSV or PI. Women with polycystic ovaries had a higher mean ovarian artery PSV on all the three occasions of measurement. CONCLUSION: These data suggest that assessment of ovarian blood flow before commencement of gonadotropin stimulation may play a role in assessing cycles likely to result in pregnancy.  (+info)

Mirna-93 inhibits glut4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin...Mirna-93 inhibits glut4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin...
TY - JOUR. T1 - Mirna-93 inhibits glut4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. AU - Chen, Yen-Hao. AU - Heneidi, Saleh. AU - Lee, Jung Min. AU - Layman, Lawrence C.. AU - Stepp, David W.. AU - Gamboa, Gloria Mabel. AU - Chen, Bo Shiun. AU - Chazenbalk, Gregorio. AU - Azziz, Ricardo. PY - 2013/7. Y1 - 2013/7. N2 - Approximately 70% of women with polycystic ovary syndrome (PCOS) have intrinsic insulin resistance (IR) above and beyond that associated with body mass, including dysfunctional glucose metabolism in adipose tissue (AT). In AT, analysis of the IRS/PI3- K/AKT pathway signaling components identified only GLUT4 expression to be significantly lower in PCOS patients and in control subjects with IR. We examined the role of miRNAs, particularly in the regulation of GLUT4, the insulin-sensitive glucose transporter, in the AT of PCOS and matched control subjects. PCOS AT was determined to have a differentially expressed ...
the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome - Full Text...the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome - Full Text...
Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to affect more than 5% of the population and is associated with chronically elevated serum androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive disease during pregnancy,and preterm birth,which is partially related with the hyperandrogenic environment.Diane-35 has been proved to be the most effective anti-androgenic drug.At present, there is no direct evidence that Diane-35 has a positive effect on the clinical outcome of polycystic ovary syndrome patients undergoing In-vitro fertilization/Intracytoplasmic sperm injection ...
Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome - Full Text View - ClinicalTrials.govInsulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome - Full Text View - ClinicalTrials.gov
The polycystic ovary syndrome is the leading cause of female infertility in the United States. The disorder affects approximately 6-10% of women of reproductive age. Insulin is a hormone that helps the body to take up sugar from the bloodstream. It is widely accepted that insulin resistance may be responsible for the polycystic ovary syndrome. Women are insulin resistant when their bodies do not respond to insulins action to handle sugar as they normally should. Because of this insulin resistance, when women with the polycystic ovary syndrome become pregnant, they are at a higher risk of developing gestational diabetes. Gestational diabetes carries risk to both the mother and the baby. The purpose of this study is to determine whether certain factors in women with the polycystic ovary syndrome are linked to risk of gestational diabetes. We propose to look at demographic factors, as well as the bodys handling of estrogen (a female hormone present in high quantities during pregnancy) in this ...
Polycystic ovary syndrome: MedlinePlus GeneticsPolycystic ovary syndrome: MedlinePlus Genetics
The causes of polycystic ovary syndrome are complex. This condition results from a combination of genetic, health, and lifestyle factors, some of which have not been identified. Common variations (polymorphisms) in several genes have been associated with the risk of developing polycystic ovary syndrome. Because they are common, these variations can be present in people with polycystic ovary syndrome and in those without. It is the combination of these changes that helps determine a womans likelihood of developing the disease.. Genes that are involved in many body processes are thought to play a role in the development of polycystic ovary syndrome. The main contributors are likely genetic variants that increase the production of androgens and other sex hormones such as luteinizing hormone and anti-Mullerian hormone, which both play key roles in ovulation. Other genetic variants likely involved in a decrease in follicle-stimulating hormone are thought to contribute to the poor development of ...
Polycystic Ovary Syndrome (PCOS) Explained - LovelibraPolycystic Ovary Syndrome (PCOS) Explained - Lovelibra
You may have heard the term Polycystic Ovary Syndrome before, or the abbreviation of PCOS. But, what does that even mean? Were about to give you the Libra lowdown. Lets do this…. What is Polycystic Ovary Syndrome, and what causes it?. Basically, girls produce the hormone oestrogen, whereas guys have all of that brooding testosterone. The plot twist? In addition to oestrogen, us gals have these things called androgens. (Bear with us, this can get kinda confusing). These are male hormones that females also make.. Sometimes, ovaries pump out more androgens than whats considered normal, and this is called hyperandrogenism. These high levels of male hormones can tamper with our healthy ovulation process, and the imbalance can even cause some weird, little follicles to grow off the ovaries. These follicles lead to the formation of cysts, and thats exactly where the cyst part of Polycystic Ovary Syndrome comes from.. Unfortunately, the exact cause of PCOS is unknown, however links have been ...
Polycystic Ovary Syndrome » Holisticme.comPolycystic Ovary Syndrome » Holisticme.com
Polycystic Ovary Syndrome (PCOS) is an endocrine system disorder that occurs in 5-10% of women of reproductive age.. What is Polycystic Ovary Syndrome?. Polycystic Ovary Syndrome (PCOS) is a condition characterized by enlargement of the ovaries, ovarian cysts, and hormone imbalance. Hormones are chemical messengers that perform vital bodily functions and have a huge impact on your health.. In PCOS the sex based hormones are out of balance, resulting in issues with the menstrual cycle, fertility, ovarian cyst formation, acne, body hair, weight gain, mood, and overall well being.. While the ovaries release a small amount of androgens (male sex hormones) in all women, in women with PCOS, the ovaries release more than required. When there is elevated androgen secretion, the follicles in the ovaries will not develop and consequently there will be no ovulation. If a woman does not ovulate then she is incapable of becoming pregnant. In addition, when no ovulation occurs it is accompanied by the ...
Polycystic Ovary Syndrome And Menopause: What You Need To Know - PharmaTimesPolycystic Ovary Syndrome And Menopause: What You Need To Know - PharmaTimes
Menopause is caused by a gradual fall in a womans hormone levels, while hormonal imbalance causes polycystic ovary syndrome. But can the reduction in sex hormones that bring on menopause cure the imbalance that causes polycystic ovary syndrome? Polycystic ovary syndrome (PCOS) is a condition that leads to cysts growing on a womans ovaries. It happens when…
Medifocus Guidebook on Polycystic Ovary SyndromeMedifocus Guidebook on Polycystic Ovary Syndrome
Centers of Research for Polycystic Ovary Syndrome - Weve compiled a unique directory of doctors, hospitals, medical centers, and research institutions with special interest and, in many cases, clinical expertise in managing people with Polycystic Ovary Syndrome. The "Centers of Research" directory is a valuable resource for quickly identifying and locating leading medical authorities and medical institutions both within the United States and other countries who are considered to be at the forefront in clinical research and treatment of Polycystic Ovary Syndrome. Youd have to spend days - or even weeks - attempting to compile your own list of doctors and medical centers but, with the "Centers of Research" directory, the information is already right at your fingertips. All you have to do is act on the information by selecting and contacting the experts or medical institutions listed in the directory by state and country. ...
Polycystic Ovary Syndrome Treatment, Treatment for Polycystic Ovary Syndrome in Bardhaman - View Doctors, Book Appointment,...Polycystic Ovary Syndrome Treatment, Treatment for Polycystic Ovary Syndrome in Bardhaman - View Doctors, Book Appointment,...
Doctors for Polycystic Ovary Syndrome in Bardhaman - Book Doctor Appointment, Consult Online, View Doctor Fees, User Reviews, Address and Phone Numbers of Doctors for Polycystic Ovary Syndrome | Lybrate
Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary...Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary...
1. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of Impaired Glucose Tolerance and Diabetes in Women with Polycystic Ovary Syndrome. Diabetes Care. 1999;22(1):141-6. doi: 10.2337/diacare.22.1.141 10333916. 2. Joham AE, Ranasinha S, Zoungas S, Moran L, Teede HJ. Gestational Diabetes and Type 2 Diabetes in Reproductive-Aged Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2014;99(3):E447-52. doi: 10.1210/jc.2013-2007 24081730. 3. Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocr Rev. 1997;18(6):774-800. doi: 10.1210/edrv.18.6.0318 9408743. 4. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired Glucose Tolerance, Type 2 Diabetes and Metabolic Syndrome in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Hum Reprod Update. 2010;16(4):347-63. doi: 10.1093/humupd/dmq001 20159883. 5. Jayasena CN, Franks S. The Management of Patients with Polycystic Ovary Syndrome. Nat Rev Endocrinol. ...
polycystic ovary syndrome Disease Ontology Browser - DOID:11612polycystic ovary syndrome Disease Ontology Browser - DOID:11612
Mutations in human and/or mouse homologs are associated with this disease. Synonyms: Multicystic ovaries; Multicystic ovaries; PCOS; Polycystic Ovarian disease; Polycystic ovaries; Polycystic ovaries (disorder); polycystic ovary; Polycystic ovary syndrome; Stein-Leventhal synd.; Stein-Leventhal synd.; Stein-Leventhal syndrome; Stein-Leventhal syndrome
SART: ASRM Today - A Conversation About Polycystic Ovary Syndrome (PCOS) with Jennifer KnudtsonSART: ASRM Today - A Conversation About Polycystic Ovary Syndrome (PCOS) with Jennifer Knudtson
PCOS is actually the most common endocrine disorder among reproductive age women. In 2010, according to the WHO it estimated 116 million women worldwide have PCOS. - Jennifer Knudtson, M.D. It has been 30 years since the National Institutes of Health issued criteria on polycystic ovary syndrome or PCOS and we talk about the most recent updated guidelines today with Dr. Jennifer Knudtson, M.D. Dr. Jennifer Knudtson is an Associate Professor in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility at University of Texas Health, San Antonio. She is a CREST scholar and a member of the ASRM Patient Education Committee, representing the Society for the Study of Reproductive Endocrinology and Infertility (SREI). ASRM Practice Committee documents mentioned in this episode: Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome (2018) Role of metformin for ovulation induction in infertile patients with polycystic
Polycystic ovary syndrome | Archives of Disease in ChildhoodPolycystic ovary syndrome | Archives of Disease in Childhood
The symptoms of PCOS often date from adolescence and it is no surprise that polycystic ovaries are commonly found in teenagers with menstrual disturbances and/or hirsutism. The typical biochemical abnormalities are often present but it is important to be aware that, as in adults, serum concentrations of LH or testosterone (even in hirsute subjects) may be normal and should not prohibit the diagnosis of PCOS, which is made, primarily, on clinical and ultrasonographic criteria. Polycystic ovaries can be identified on ultrasound, even in prepubertal children. The prevalence of polycystic ovaries increases throughout puberty, reaching 26% by the age of 15.12 Full expression of clinical and endocrine features of polycystic ovary syndrome depends on the maturational changes in the hypothalamic-pituitary-ovarian axis which occur during normal puberty, notably the influence of gonadotrophins on ovarian steroidogenesis. The presence of polycystic ovaries before the onset of puberty suggests that the ...
Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome<...Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome<...
TY - JOUR. T1 - Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome. AU - Legro, Richard S.. PY - 2002. Y1 - 2002. N2 - Polycystic ovary syndrome (PCOS) appears to be a lifelong disorder. The stigmata of insulin resistance, including obesity and premature adrenarche, may be early forms of its presentation. Girls with premature pubarche, characterized by elevated dehydroepiandrosterone levels and hyperinsulinemia, are at high risk for developing the full PCOS phenotype, including ovarian hyperandrogenism and chronic anovulation. Because PCOS is associated with a 40% prevalence of abnormal glucose tolerance, every adolescent patient should be evaluated regularly for glucose intolerance with a 2-hour oral glucose tolerance test and for lipid abnormalities with a fasting lipid profile. The role of insulin-sensitizing medications such as metformin in adolescents with PCOS is unclear; short-term studies suggest that these agents improve circulating androgens ...
Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)<...Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)<...
TY - JOUR. T1 - Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). AU - Dunaif, Andrea. AU - Wu, Xinqi. AU - Lee, Anna. AU - Diamanti-Kandarakis, Evanthia. PY - 2001/8/27. Y1 - 2001/8/27. N2 - Women with polycystic ovary syndrome (PCOS) are insulin resistant secondary to a postbinding defect in insulin signaling. Sequential euglycemic glucose clamp studies at 40 and 400 mU·m-2·min-1 insulin doses with serial skeletal muscle biopsies were performed in PCOS and age-, weight-, and ethnicity-matched control women. Steady-state insulin levels did not differ, but insulin-mediated glucose disposal was significantly decreased in PCOS women (P , 0.05). Insulin receptor substrate (IRS)-1-associated phosphatidylinositol 3-kinase (PI 3K) activity was significantly decreased in PCOS (n = 12) compared with control skeletal muscle (n = 8; P , 0.05). There was no significant difference in the abundance of IR, IRS-1, or the p85 regulatory subunit of PI 3K in PCOS (n = 14) ...
Polycystic Ovarian DiseasePolycystic Ovarian Disease
... - Increasingly Diagnosed Polycystic Ovarian Disease (PCO) is a condition being recognized in women with increased frequency. Women with PCO can have a
Polycystic Ovarian Disease| Houston MethodistPolycystic Ovarian Disease| Houston Methodist
We offer a variety of treatment options for polycystic ovarian disease. Learn more about the symptoms of polycystic ovarian disease and other gynecology conditions at Houston Methodist.
Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome<...Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome<...
TY - JOUR. T1 - Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. AU - Brennan, Kathleen. AU - Huang, Andy. AU - Azziz, Ricardo. N1 - Copyright: Copyright 2009 Elsevier B.V., All rights reserved.. PY - 2009/5. Y1 - 2009/5. N2 - Objective: To test the hypothesis that increasing DHEAS levels is associated with improved insulin resistance in patients with polycystic ovary syndrome (PCOS). Design: Cross-sectional cohort analysis. Setting: Academic medical center. Patient(s): Three hundred fifty-two women with PCOS. Intervention(s): Patients presenting for evaluation of symptoms related to androgen excess were evaluated physically and biochemically through laboratory analysis. Main Outcome Measure(s): Circulating DHEAS, total T, free T, sex hormone-binding globulin (SHBG), and 17-hydroxyprogesterone (17-OHP) levels, and calculated homeostasis model assessment of insulin resistance (HOMA-IR). Result(s): Bivariate analysis indicated that all parameters ...
Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome<...Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome<...
TY - JOUR. T1 - Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome. AU - Chen, Chin I.. AU - Hsu, Ming-I. AU - Lin, Shyh-Hsiang. AU - Chang, Yuan Chin Ivan. AU - Hsu, Chun-Sen. AU - Tzeng, Chii-Ruey. PY - 2015/4/1. Y1 - 2015/4/1. N2 - Aim: The objective of this study was to evaluate the adiponectin and leptin levels in overweight/obese and lean women with polycystic ovary syndrome (PCOS). Design: This was a retrospective study. Patients: Of the 422 studied patients, 224 women with PCOS and 198 women without PCOS were evaluated. Main outcome measure(s): Insulin resistance and the metabolic components were assessed. The adiponectin and leptin levels were also evaluated. Results: Adiponectin was negatively correlated with insulin resistance, body mass index (BMI), and total testosterone, triglyceride, and low-density lipoprotein (LDL) levels; conversely, leptin reversed the aforementioned reaction and was negatively correlated with adiponectin levels. The ...
Polycystic Ovary Syndrome (PCOS) | eclaireMDPolycystic Ovary Syndrome (PCOS) | eclaireMD
Polycystic ovary syndrome or PCOS is a common hormonal disorder in women and it involves multiple organs in the body. Even though the name implied multiple cysts in the ovaries, some women may not have cysts in the ovaries. It is estimated that about 5 to 10 percent of women in the U.S have polycystic ovary syndrome.PCOS is often found in women who are in their childbearing age but it can also occur in young girls who just reach puberty.Currently, research studies showed that PCOS runs in the families. If your mother or sister is diagnosed with PCOS, you are at higher chance for having it.. Scientists do not know the exact causes of PCOS yet. Nevertheless, it is found to be associated with imbalance of several hormones including estrogen and progesterone (female hormones), androgen (male hormone), LH and FSH (from pituitary gland in the brain) and insulin. Insulin is the hormone that regulates blood glucose. In a normal menstrual cycle, LH, FSH, estrogen and progesterone play a role in oocyte ...
Polycystic ovary syndrome: Possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes...Polycystic ovary syndrome: Possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes...
TY - JOUR. T1 - Polycystic ovary syndrome. T2 - Possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes/macrophages. AU - Lima, Patricia D.A.. AU - Nivet, Anne Laure. AU - Wang, Qi. AU - Chen, Yi An. AU - Leader, Arthur. AU - Cheung, Annie. AU - Tzeng, Chii Ruey. AU - Tsang, Benjamin K.. PY - 2018/10/1. Y1 - 2018/10/1. N2 - Polycystic ovary syndrome (PCOS) is a continuum of endocrine and reproductive disorders characterized by hyperandrogenism, antral follicle growth arrest, and chronic inflammation. Macrophages play key role in inflammation, and the balance between M1 (inflammatory) and M2 (anti-inflammatory) macrophages determines physiological/pathological outcomes. Here, we investigated if hyperandrogenism increases ovarian chemerin altering the balance of M1 and M2 macrophages and the granulosa cell death. Ovarian chemerin was upregulated by 5α-dihydrotestosterone (DHT) in lean and overweight rats; while increased serum chemerin levels were only evident ...
Difference in dietary intake between women with polycystic ovary syndrome and healthy controls<...Difference in dietary intake between women with polycystic ovary syndrome and healthy controls<...
TY - JOUR. T1 - Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. AU - Douglas, Crystal. AU - Norris, Leigh E.. AU - Oster, Robert A.. AU - Darnell, Betty E.. AU - Azziz, Ricardo. AU - Gower, Barbara A.. PY - 2006/8/1. Y1 - 2006/8/1. N2 - Objective: To test the hypothesis that the dietary intake and dietary composition of women with polycystic ovary syndrome (PCOS) is associated with indices of glycemic status. We hypothesized that women with PCOS would consume a diet higher in total energy, fat, and specific foods with a high glycemic index than would healthy, control-group women and that dietary composition would be associated with indices of insulin resistance and secretion among women with PCOS. Design: Cohort study. Setting: Research center on a university campus. Patient(s): Thirty women with PCOS and 27 healthy, age-, race-, and body mass index (BMI)-matched control women. Intervention(s): None. Main Outcome Measure(s): Nutrient intake data ...
What is Polycystic Ovary Syndrome (PCOS)? - Definition from FertilitySmartsWhat is Polycystic Ovary Syndrome (PCOS)? - Definition from FertilitySmarts
Polycystic Ovary Syndrome PCOS Definition - Polycystic ovary syndrome (PCOS) is a hormone (endocrine) disorder in which a womens levels of estrogen and...
How to Get Pregnant With Polycystic Ovary Syndrome (PCOS)How to Get Pregnant With Polycystic Ovary Syndrome (PCOS)
... Polycystic ovary syndrome (PCOS) affects 5 to 10 percent of women who are of child-bearing age. It is a hormonal disorder that causes obesity, acne, hair growth, and is one of the...
Polycystic ovary syndrome/Disease (PCOS or PCOD) SymptomsPolycystic ovary syndrome/Disease (PCOS or PCOD) Symptoms
... - Click to know more on symptoms of Polycystic ovary syndrome/Disease (PCOS or PCOD) ! @AskDabur
Home Remedies and Herbs for Polycystic Ovary Syndrome (PCOS)Home Remedies and Herbs for Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome (PCOS) natural treatment. Find out the most effective home remedies, herbs, supplements and natural products for Polycystic Ovary Syndrome (PCOS)
Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats |...Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats |...
Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive age. The study was commenced to assess the favorable effects of Rutin against metabolic, biochemical, histological, and androgenic aspects of polycystic ovary syndrome in rats. Female Sprague-Dawley rats were administered letrozole (1 mg/kg) per orally (p.o) for a period of 21 days for the induction of PCOS, followed by dose of rutin (100 mg/kg and 150 mg/kg, p.o) for 15 days using 0.5% w/v CMC as vehicle. Metformin was also given as a standard control to one of the rat groups. Serum estradiol, progesterone, testosterone, serum lipid parameters, CRP and glucose levels were evaluated. Furthermore, antioxidant activity was tested using superoxide dismutase, catalase, glutathione per-oxidase and reactive-oxygen species level. Rutin flavonoid had a dose-dependent effect on androgenic levels depicting more recovery in the rutin-I treated group, while rutin-II treated groups showed better antioxidant and lipid
Polycystic ovary syndrome guideline released for public consultation - ACDPolycystic ovary syndrome guideline released for public consultation - ACD
The National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Polycystic Ovary Syndrome (CREPCOS) has released the updated evidence-based guideline for the assessment and management of polycystic ovary syndrome for public consultation. The guidelines include recommendations on clinical hyperandrogenism including acne, female pattern hair loss and hirsutism.. The consultation period is open until Monday 12 March 2018. For more information, visit the CREPCOS website ...
Polycystic Ovary Syndrome (PCOS) Treatment in Murrells Inlet, SCPolycystic Ovary Syndrome (PCOS) Treatment in Murrells Inlet, SC
Polycystic Ovary Syndrome (PCOS) diagnosis and treatment in Murrells Inlet, SC. Diagnosis and treatment of Polycystic Ovary Syndrome by local hormone specialist.
Fresh Versus Frozen Embryos For Infertility In The Polycystic Ovary SyndromeFresh Versus Frozen Embryos For Infertility In The Polycystic Ovary Syndrome
Frozen embryo transfer during IVF may improve chances for pregnancy in women with polycystic ovary syndrome.. (HealthDay News) - For women with polycystic ovary syndrome (PCOS) seeking infertility treatment, the use of frozen embryos rather than fresh appears to improve the chances for a successful pregnancy, according to a study published in the New England Journal of Medicine.. Richard Legro, MD, a professor of obstetrics and gynecology and public health sciences at Pennsylvania State University in Hershey, and colleagues randomly assigned 1508 infertile Chinese women who had PCOS and who were having their first in vitro fertilization (IVF) cycle to use either fresh or frozen embryo transfer.. Continue Reading Below. The researchers found a higher frequency of live birth after the first transfer when frozen embryos were used (49.3%) than when fresh embryos were implanted (42.0%). At the same time, there was a slightly higher risk of preeclampsia (4.4% vs 1.4%), and newborn death (5 deaths vs ...
The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome<...The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome<...
TY - CHAP. T1 - The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome. AU - Legro, Richard. PY - 2010/1/1. Y1 - 2010/1/1. N2 - Insulin-sensitising agents are frequently used in the treatment of women with polycystic ovary syndrome (PCOS) but, to date, the results have fallen short of expectations. Despite their limited benefits, these drugs are widely used in PCOS, and they are probably overprescribed. Insulin-sensitising agents are a class of drugs that work primarily or in part by improving peripheral insulin sensitivity to lower insulin levels and, ultimately, to lower circulating glucose levels. The classic example is the thiazolidinediones (pioglitazone and rosiglitazone). Given the intense endocrine interaction of tissues involved in glucose homeostasis, drugs that target one organ or function often have cross-over benefit on other aspects of glucose homeostasis. For instance, the biguanides primarily suppress hepatic gluconeogenesis but also exert some ...
Polycystic Ovary Syndrome: The Common Disease Youve Never Heard Of - Star & CrescentPolycystic Ovary Syndrome: The Common Disease You've Never Heard Of - Star & Crescent
Almost 1 in 10 women in the UK are diagnosed with Polycystic Ovary Syndrome - why dont we know more about it? Portsmouth-based blogger and broadcaster Laura Mitchell finds out why. In August 2016, I sought advice from my GP for a painful case of acne that had been breaking out on my face for the best part of a year. Around the same time, my periods became irregular; they lost sync for six months, and for the next five stopped altogether.. My GP gave me antibiotics for the acne, but also questioned me on other points. Did I find it difficult to lose weight? Yes - dont we all? Was my hair thinning and falling out? No. I had always had a thick mane of hair.. He rubbed his chin and told me he would like to send me for blood tests. He thought I might have a condition called polycystic ovary syndrome.. Nothing more was said until my blood results came back. My hormone levels were in check, so it was unlikely I had PCOS. However, I was sent for an ultrasound to be sure. The scan showed my ovaries had ...
Current trends in the treatment of polycystic ovary syndrome with desi | TCRMCurrent trends in the treatment of polycystic ovary syndrome with desi | TCRM
Current trends in the treatment of polycystic ovary syndrome with desire for children Margalida E Sastre1, Maria O Prat1, Miguel Angel Checa1,2, Ramon C Carreras11Department of Obstetrics and Gynaecology; 2Unit of Endocrinological Gynaecology and Human Reproduction, Hospital del Mar, Autonomous University of Barcelona, Barcelona, SpainAbstract: Polycystic ovary syndrome (PCOS), one of the most frequent endocrine diseases, affects approximately 5%–10% of women of childbearing age and constitutes the most common cause of female sterility regardless of the need or not for treatment, a change in lifestyle is essential for the treatment to work and ovulation to be restored. Obesity is the principal reason for modifying lifestyle since its reduction improves ovulation and the capacity for pregnancy and lowers the risk of miscarriage and later complications that may occur during pregnancy (gestational diabetes, pre-eclampsia, etc). When lifestyle modification is not sufficient, the first step in
Polycystic Ovary SyndromePolycystic Ovary Syndrome
... is a chronic lifelong condition that often leads to infertility. What is Polycystic Ovary Syndrome and what are the Symptoms?
Polycystic Ovary Syndrome In Adolescence in Hyderabad - View Cost, Book Appointment, Consult OnlinePolycystic Ovary Syndrome In Adolescence in Hyderabad - View Cost, Book Appointment, Consult Online
Doctors for Polycystic Ovary Syndrome In Adolescence in Hyderabad. Find Doctors Near You, Book Doctors Appointment, Consult Online, View Cost for Polycystic Ovary Syndrome In Adolescence in Hyderabad | Lybrate
The role of vitamin d in polycystic ovary syndrome and its metabolic Dysregulations: A case control study | International...The role of vitamin d in polycystic ovary syndrome and its metabolic Dysregulations: A case control study | International...
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting the women of reproductive age. Vitamin D deficiency may have a role in etiopathogenesis of PCOS and its metabolic and endocrine dysregulations. Various studies have shown conflicting results regarding role of vitamin D in PCOS. Therefore, the aim of this study was to find out vitamin D status in PCOS and its association with various metabolic dysregulations. Methods: This single center prospective case control study included 100 females with PCOS and 100 controls. Participates were evaluated for vitamin D status. Correlation of vitamin D with metabolic dysregulations in PCOS was then done. Results: Vitamin D deficiency was seen in 102 (51%) participants. Vitamin D levels were lower in PCOS group compared to control group (20.9 ± 10.2 vs 27.0 ± 15.6, P value 0.001). Prevalence of Vitamin D deficiency was also more in PCOS group compared to control group (59% vs 43 %, P value 0.024).Vitamin D levels were ...
Women Health: Obesity polycystic ovary syndrome (PCOS) and insulin resistanceWomen Health: Obesity polycystic ovary syndrome (PCOS) and insulin resistance
Approximately 50% to 70% of women with polycystic ovary syndrome (PCOS) have some degree of insulin resistance, and obesity is known to worsen insulin resistance. According to the study by the Ewha Womans University School of Medicine, posted in PubMed, ISI was significantly lower in both lean and ow/ob women with PCOS compared to BMI-matched controls (p,0.05). Increasing BMI by 1 kg/m(2) decreased ISI by 0.169 in PCOS patients (p,0.05) and by 0.238 in controls (p,0.05); there was no significant difference between these groups. In lean PCOS patients and lean controls, BMI had no effect on ISI. Multiple regression analysis revealed that PCOS status (β=-0.423, p,0.001) and BMI (β=-0.375, p,0.001) were significantly associated with ISI. Conclusion: Insulin resistance is an intrinsic defect of PCOS, and a high BMI could exacerbate insulin resistance in all women, irrespective of whether they have PCOS. ...
Infertility in polycystic ovary syndrome - WikipediaInfertility in polycystic ovary syndrome - Wikipedia
Infertility in polycystic ovary disease (PCOS) is a hormonal imbalance in women that is thought to be one of the leading causes of female infertility. Polycystic ovary syndrome causes more than 75% of cases of anovulatory infertility. Not all women with PCOS have difficulty becoming pregnant.[citation needed] For those who do, anovulation is a common cause. The mechanism of this anovulation is uncertain, but there is evidence of arrested antral follicle development, which, in turn, may be caused by abnormal interaction of insulin and luteinizing hormone (LH) on granulosa cells. Endocrine disruption may also directly decrease fertility, such as changed levels of gonadotropin-releasing hormone, gonadotropins (especially an increase in luteinizing hormone), hyperandrogenemia, and hyperinsulinemia. Gonadotropins are released by gonadotroph cells in pituary gland, and these cells appear to harbor insulin receptors, which are affected by elevated insulin levels. A reason that insulin sensitizers work ...
Data mining polycystic ovary morphology in electronic medical record ultrasound reports | Fertility Research and Practice |...Data mining polycystic ovary morphology in electronic medical record ultrasound reports | Fertility Research and Practice |...
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenemia, oligo-anovulation, and numerous ovarian cysts. Hospital electronic medical records provide an avenue for investigating polycystic ovary morphology commonly seen in PCOS at a large scale. The purpose of this study was to develop and evaluate the performance of two machine learning text algorithms, for classification of polycystic ovary morphology (PCOM) in pelvic ultrasounds. Pelvic ultrasound reports from patients at Boston Medical Center between October 1, 2003 and December 12, 2016 were included for analysis, which resulted in 39,093 ultrasound reports from 25,535 unique women. Following the 2003 Rotterdam Consensus Criteria for polycystic ovary syndrome, 2000 randomly selected ultrasounds were expert labeled for PCOM status as present, absent, or unidentifiable (not able to be determined from text alone). An ovary was marked as having PCOM if there was mention of numerous peripheral follicles or if the volume was greater than 10
Effect of finasteride on ovulation induction in nonresponder (hyperandrogenic) polycystic ovary syndrome (PCOS) women | IRIS...Effect of finasteride on ovulation induction in nonresponder (hyperandrogenic) polycystic ovary syndrome (PCOS) women | IRIS...
Objective: To evaluate whether the addition of finasteride (a 5 ,-reductase inhibitor) to conventional protocol of ovarian stimulation with gonadotropin can improve ovarian follicular growth in polycystic ovary syndrome (PCOS) women who did not respond to previous stimulation with gonadotropin alone. Design: Double-blind randomized study. Setting: Outpatient in an academic research environment. Patient(s): Thirty-six PCOS patients in whom the previous multifollicular stimulation protocols with gonadotropin failed. Intervention(s): The patients were randomly assigned to two treatment groups: group 1 underwent ovarian stimulation with recombinant FSH (rFSH) plus finasteride, and group 2 received rFSH alone. When the dominant follicle reached a mean diameter of 18 mm, hCG was administered and finasteride withdrawn. Main Outcome Measure(s): Ovulation rate in women with PCOS. Result(s): Follicular growth and ovulation occurred in eight patients in group 1, whereas no cases were detected in group 2. ...
Serum Adiponectin levels in Different Phenotypes of Polycystic Ovary SyndromeSerum Adiponectin levels in Different Phenotypes of Polycystic Ovary Syndrome
ABSTRACT. Objectives: to evaluate and compare serum adiponectin levels in different phenotypes of polycystic ovary syndrome (PCOS) and to investigate their correlation with endocrine and metabolic parameters. Material and methods: we studied 5 groups of patients: A (n = 20): H (hyperandrogenism) + O (oligoanovulation) + P (polycystic ovary) [classic phenotype]; B (n = 17): H + O [classic phenotype but normal ovaries]; C (n = 15): H + P [Ovulatory phenotype]; D (n = 17): O + P [Normoandrogenic phenotype]; and E (n = 16) control group. Body mass index, waist circumference, waist/hip ratio, blood pressure and hirsutism were evaluated. Serum concentrations of adiponectin, insulin, Creactive protein, SHBG, androgens and lipids were measured. Oral glucose tolerance test was performed. Results: there were no differences between the groups in terms of age and BMI. Total cholesterol, LDL-C and triglyceride levels were higher in phenotype A than in C (P < 0.05); HDL-C was slightly lower in phenotype D ...
Hope for PCOS: Nutrients improve symptoms in polycystic ovary syndrome - Betsys Health FoodsHope for PCOS: Nutrients improve symptoms in polycystic ovary syndrome - Betsy's Health Foods
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of child-bearing age, with symptoms including irregular periods, elevated male hormone levels, and enlarged ovaries. Untreated, the syndrome can lead to type 2 diabetes and other health problems. According to the PCOS Awareness Association, some of the potential issues women face who suffer from…
Polycystic Ovarian Syndrome Treatment Market Will Reflect Significant Growth Prospects during 2019-2028 | Sanofi S.A.,Pfizer...Polycystic Ovarian Syndrome Treatment Market Will Reflect Significant Growth Prospects during 2019-2028 | Sanofi S.A.,Pfizer...
Laparoscopic Ovarian Drilling. Table of Contents - Major Key Points. Part 01: Polycystic Ovarian Syndrome Treatment Market Overview. Part 02: Manufacturers Profiles. Part 03: Global Polycystic Ovarian Syndrome Treatment Market Competition, by Players. Part 04: Global Polycystic Ovarian Syndrome Treatment Market Size by Regions. Part 05: North America Polycystic Ovarian Syndrome Treatment Revenue by Countries. Part 06: Europe Polycystic Ovarian Syndrome Treatment Revenue by Countries. Part 07: Asia-Pacific Polycystic Ovarian Syndrome Treatment Revenue by Countries. Part 08: South America Polycystic Ovarian Syndrome Treatment Revenue by Countries. Part 09: Middle East and Africa Revenue Polycystic Ovarian Syndrome Treatment by Countries. Continued…. Report synopsis. • To investigate the market size of the market and induce the key trends from it. • Industry Chain Suppliers of Polycystic Ovarian Syndrome Treatment market with Contact Information • Authentic, current and anticipated market ...
Polycystic ovary syndrome - Genetics Home ReferencePolycystic ovary syndrome - Genetics Home Reference
Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.. Most women with polycystic ovary syndrome produce excess male sex hormones (androgens), a condition called hyperandrogenism. Having too much of these hormones typically leads to excessive body hair growth (hirsutism), acne, and male pattern baldness.. Hyperandrogenism and abnormal levels of other sex hormones prevent normal release of egg cells from the ovaries (ovulation) and regular menstrual periods, leading to difficulty conceiving a child (subfertility) or a complete inability to conceive (infertility). For those who achieve pregnancy, there is an increased risk of complications and pregnancy loss. Due to irregular and infrequent menstruation and hormone abnormalities, affected women have an increased risk of cancer of the uterine lining (endometrial cancer).. In polycystic ovary syndrome, multiple cysts in ...
Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists<...Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists<...
TY - JOUR. T1 - Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. AU - Farah, Lisa. AU - Lazenby, A. Jan. AU - Boots, Larry R.. AU - Azziz, Ricardo. PY - 1999/10/1. Y1 - 1999/10/1. N2 - OBJECTIVE: To determine the prevalence of the poly- cystic ovary syndrome (PCOS) among women seeking electrology, clients presenting to nine electrology centers completed a questionnaire. STUDY DESIGN: Women with potential risk factors were referred to the University of Alabama at Birmingham. They underwent a detailed history and physical examination, including hirsutism scoring by a modified Ferriman-Gallwey (F-G) method. Serum was assayed for total testosterone, sex hormone binding globulin and dehydroepiandrosterone sulfate. RESULTS: Three hundred fifteen (40%) of 779 patients had potential riskfactors for hyperandrogenism and were referred. Eighty-two (26%) completed their evaluation. Six were excluded secondary to prepubertal or menopausal status. Of the ...
Polycystic ovary syndrome and endometrial hyperplasia: an overview of the role of bariatric surgery in female fertility. - UHB...Polycystic ovary syndrome and endometrial hyperplasia: an overview of the role of bariatric surgery in female fertility. - UHB...
One of the most effective methods to tackle obesity and its related comorbidities is bariatric surgery. Polycystic ovary syndrome (PCOS) and endometrial hyperplasia (EH), which are associated with increased risk of endometrial carcinoma, have been identified as potentially new indications for bariatric surgery. PCOS is the most common endocrine disorder in women in the reproductive age and is associated with several components of the metabolic syndrome such as obesity, insulin resistance and hypertension. EH is a pre-cancerous condition which arises in the presence of chronic exposure to estrogen unopposed by progesterone such as both in PCOS and obesity. The main bariatric procedures are Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. These procedures are well established and when correctly selected and performed by experienced bariatric surgeons, they can achieve significant weight loss and remission of obesity related co-morbidities. ...
Metformin Administration is More Effective When Non-Obese Patients With Polycystic Ovary Syndrome Show Both Hyperandrogenism...Metformin Administration is More Effective When Non-Obese Patients With Polycystic Ovary Syndrome Show Both Hyperandrogenism...
By Genazzani, Alessandro D; Lanzoni, Chiara; Ricchieri, Federica; Baraldi, Enrica; Et al Abstract Background. Polycystic ovary syndrome (PCOS) is a common endocrine disease that is frequently observed to be related to increased insulin resistance independent of body weight. The use of insulin-sensitizer compounds, such as metformin, permits great improvement of such metabolic abnormality, restoring ovarian function and gonadal steroid synthesis and reducing insulin resistance. Aim. On this basis we aimed to evaluate a group of non-obese amenorrheic PCOS patients before and after 6 months of metformin administration (500 mg orally twice daily) to better understand upon which basis of clinical and endocrine parameters metformin administration might be chosen as a putative therapeutic tool. Method. A group of non-obese PCOS patients (n = 42) was enrolled after informed consent. They underwent an oral glucose tolerance test for insulin, glucose and C-peptide levels and provided blood samples for ...
Effects of Progressive Resistance Training on Obesity Indices in Polycystic Ovary Syndrome and the Relationship With Telomere...Effects of Progressive Resistance Training on Obesity Indices in Polycystic Ovary Syndrome and the Relationship With Telomere...
Background: Physical activity is prescribed as a component of primary management for polycystic ovary syndrome (PCOS). This nonrandomized, therapeutic, open, single-arm study investigated the effects of progressive resistance training (PRT) on obesity indices in women with PCOS, and the relationship between obesity indices and telomere content. Methods: A total of 45 women with PCOS and 52 with non-PCOS (controls), aged 18 to 37 years, with body mass indexes of 18 to 39.9 kg/m2, performed three 1-hour sessions of PRT per week, for 16 weeks. Before and after PRT, measures included anthropometric indices and regions of interest of fat mass distribution, quantified by dual-energy X-ray absorptiometry, metabolic and hormonal parameters, and telomere content. The general linear mixed models were used to determine the effects of PRT. Results: PRT did reduce the waist-to-height ratio, waist circumference, and the index of conicity among PCOS (P , .01). However, PRT did not influence regions of ...
Center for Health Research, Inc.; Female Pattern Baldness, loss of libido, PMS symptom, alopecia, polycystic ovarian disease,...Center for Health Research, Inc.; Female Pattern Baldness, loss of libido, PMS symptom, alopecia, polycystic ovarian disease,...
Female Pattern Baldness: Specializing in loss of libido, PMS symptom, alopecia, polycystic ovarian disease, menopause, PMS, chronic fatigue syndrome, PCOS, polycystic ovarian, insulin resistance, and PMDD
Polycystic Ovary Syndrome, Acupuncture treatment in Bristol @ Bristol Acupuncture PracticePolycystic Ovary Syndrome, Acupuncture treatment in Bristol @ Bristol Acupuncture Practice
Polycystic Ovary Syndrome, Acupuncture treatment in Bristol, PCOS or Polycystic Ovarian Syndrome, periods and fertility pregnancy
Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone...Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone...
In this present study, we compared the AMH levels among four groups according to the presence of PCOS and PCOM. Serum AMH level was the highest in group 1 (HA + OM + PCOM) and the lowest in group 4 (control). Women with PCOS had higher serum AMH levels than did regular cycling women, regardless of the presence of PCOM, and women with PCOM had higher serum AMH levels than did women without PCOM, regardless of the presence of PCOS.. AMH was positively associated with HA only in women with PCOS, not in regular cycling women regardless of the presence of PCOM. We also observed that serum AMH level did not differ between the five age groups (, 20, 20 to 24, 25 to 29, 30 to 34, and ≥ 35 years). The AMH optimal cutoff value for PCOS diagnosis was 10.5 ng/mL in young Korean women.. The association of AMH level with HA observed in our study was consistent with the finding of previous studies that AMH level was positively correlated with symptom severity in PCOS [19,20]. AMH concentration was previously ...
Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review | Journal of Ovarian...Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review | Journal of Ovarian...
Polycystic ovary syndrome (PCOS) is a polygenic endocrine disorder and the most common gynecological endocrinopathy among reproductive-aged women. Current remedies are often used only to control its signs and symptoms, while they are not thoroughly able to prevent complications. Quercetin is an herbal bioactive flavonoid commonly used for the treatment of metabolic and inflammatory disorders. Thus, this systematic review was conducted to evaluate the efficacy of quercetin supplementation in subjects with PCOS. Databases until March 2019 were searched. All human clinical trials and animal models evaluating the effects of quercetin on PCOS women were included. Out of 253 articles identified in our search, 8 eligible articles (5 animal studies and 3 clinical trials) were reviewed. The majority of studies supported the beneficial effects of quercetin on the ovarian histomorphology, folliculogenesis, and luteinisation processes. The effects of quercetin on reducing the levels of testosterone, luteinizing
Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A...Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A...
Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Three-Arm, Open-label, Randomized, Controlled Trial
Serum Fetuin-A levels are increased and associated with insulin resistance in women with polycystic ovary syndrome | BMC...Serum Fetuin-A levels are increased and associated with insulin resistance in women with polycystic ovary syndrome | BMC...
Insulin resistance (IR) is a common characteristic of women with polycystic ovary syndrome (PCOS). It has been reported that circulating Fetuin-A levels were associated with IR and type 2 diabetes mellitus (T2DM). However, previous reports were inconsistent. Two hundred seven subjects were screened for PCOS according to the diagnostic guideline of the Rotterdam consensus criterion. Serum Fetuin-A levels were measured using an ELISA kit. An independent t-test or Nonparametric test was used to detect differences between PCOS and control groups. Spearmans correlation analysis was used to examine the association of the serum Fetuin-A with other parameters. Our findings showed that circulating Fetuin-A concentration ranged from 196.6 to 418.2 μg/L for most women without PCOS (95%). Women with PCOS had higher circulating Fetuin-A levels than healthy women (437.9 ± 119.3 vs. 313.8 ± 60.5 μg/L; p | 0.01). Serum Fetuin-A was positively correlated with BMI, WHR, TG, TC, LDL-C, HOMA-IR, LH, T, and DHEA-S.
Polycystic Ovary Syndrome Puts Glucose Control In Double Jeopardy - RedorbitPolycystic Ovary Syndrome Puts Glucose Control In Double Jeopardy - Redorbit
Polycystic ovary syndrome, a condition affecting about 10 percent of women and characterized by excess male hormone and increased risk of diabetes and heart disease, appears to cause a sort of double jeopardy for those struggling the hardest to control blood sugar levels, researchers report.. Humans use insulin and other non-insulin mechanisms to convert blood sugar, or glucose, into energy and control levels in the blood, where it becomes a destructive force.. A new study in the Journal of Clinical Endocrinology & Metabolism comparing 28 healthy women to 28 women with PCOS showed the latter have declines in both approaches, said Dr. Ricardo Azziz, reproductive endocrinologist and PCOS expert at Georgia Regents University.. Most surprising was the finding that the PCOS women who had the most difficulty controlling glucose via insulin were also the ones with declines in their ability to use non-insulin approaches. More typically, when insulin resistance increases, the bodys non-insulin dependent ...
NJ Holistic Doctor Michael Rothman discusses a holistic approach to Polycystic Ovary Syndrome (POS) - BizPR.ca | Canadian Free...NJ Holistic Doctor Michael Rothman discusses a holistic approach to Polycystic Ovary Syndrome (POS) - BizPR.ca | Canadian Free...
Monmouth County, NJ - "Polycystic Ovary Syndrome (PCOS) is a name given to a chronic functional problem where the patient suffers from weight gain, infertility, abnormal menstrual cycles and abnormal hair growth." So begins an article by Dr. Michael E. Rothman, New Jerseys leading holistic physician, as he explains his natural approach to curing PCOS.. The causes of PCOS, according to Dr. Rothman, are varied, including poor diet, chronic inflammation, environmental exposures, and more. It is also likely that sufferers of PCOS have elevated estrogen levels and high insulin. PCOS might also be caused by an iodine deficiency.. Dr. Rothman goes on to explain that the best solution to PCOS is a metabolically directed approach that includes dietary changes, iodine supplementation, and more. It might also include thyroid replacement therapy, removal of biotoxins, and other hormonal interventions.. ...
polycystic ovariespolycystic ovaries
This observational study included 52 Scottish women, 25 of whom had polycystic ovary syndrome (PCOS), who were tested for serum 25-hydroxyvitamin D concentrations. Vitamins D concentrations less than 25 nmol/L were classified as severe vitamin D deficiency. Severe vitamin D deficiency was found in 44% of women with PCOS and 11.2% of controls. In the PCOS group, vitamin D levels correlated negatively with body mass index, C-reactive protein and free androgen index and positively correlated with quantitative insulin sensitivity check index, HDL and sex hormone binding globulin.. Metabolism. 2011 May 5. [Epub ahead of print] Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome.. Does this mean that by adding vitamin D we can treat PCOS? Not necessarily. But with how easy it is to supplement with vitamin D, I dont see why we wouldnt add it to the regime.. Kerri. PCOS and Vitamin DRead More ...
Polycystic Ovary Syndrome (PCOS) - Barbados Fertility CenterPolycystic Ovary Syndrome (PCOS) - Barbados Fertility Center
Polycystic Ovary Syndrome (PCOS) is one of the primary causes of a womans infertility. Between 20-40 years of age, PCOS affects between 5 and 10% of women.
Polycystic Ovary Syndrome, Book by Mohgah Elsheikh (Paperback) | chapters.indigo.caPolycystic Ovary Syndrome, Book by Mohgah Elsheikh (Paperback) | chapters.indigo.ca
Buy the Paperback Book Polycystic Ovary Syndrome by Mohgah Elsheikh at Indigo.ca, Canadas largest bookstore. + Get Free Shipping on Health and Well Being books over $25!
Molecular Interactions of Polycystic Ovarian Syndrome (PCOS) with Metabolic Syndrome and Non-alcoholic Fatty Liver DiseaseMolecular Interactions of Polycystic Ovarian Syndrome (PCOS) with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease
Obesity is a common factor involved in both polycystic ovarian syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD). Obesity causes NAFLD and aggravates hirsutism and menstrual disorder in polycystic ovary syndrome (PCOS). Recent findings suggest that women with PCOS may be at risk for developing NAFLD and conversely, NAFLD patients may be a risk for PCOS. To assess the literature for associations between PCOS and NAFLD at molecular level, we performed a systematic review of peer-reviewed articles related to PCOS and NAFLD. Articles were summarized and grouped according to different sections defining interactions of PCOS with metabolic syndrome and NAFLD as well as common risk factors, pathogenic pathways and treatment options. Based on the association of PCOS and other metabolic abnormalities, such as insulin resistance, hyperandrogenism, obesity and NAFLD, the PCOS candidate genes have been proposed. Closer scrutiny of these genes placed most of their proteins at the crossroads of ...
Survivor: What is PCOS (Polycystic Ovarian Syndrome)?Survivor: What is PCOS (Polycystic Ovarian Syndrome)?
PCOS, or Polycystic Ovarian Syndrome, is a common endocrine disorder that affects one in ten women. It is often mistaken for a reproductive disorder, but it isnt. In fact, while most women have polycystic ovaries, not all women with PCOS do. Also, there are women with polycystic ovaries that do not have PCOS. Thats why there is a huge push to change the name of PCOS, because it is a misnomer. While 5% to 10% of women have PCOS, they are often misdiagnosed, or told to go to a psychiatrist for their physical and depressive issues. Women are often not taken as seriously as men in the field of medicine, in fact there are some doctors who still diagnose women with "hysteria," a bogus diagnosis that means the doctor doesnt care about his patients enough to diagnose them with their real problem. Only women had "hysteria." The diagnosis of hysteria was most commonly used in Victorian times, and was cured by an involuntary hysterectomy, or by a doctor massaging a womans genitles until she has an ...
Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary...Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary...
Clinical trial for Polycystic Ovary Syndrome , Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome
Metformin and weight loss in women with polycystic ovary syndrome (PCOS)Metformin and weight loss in women with polycystic ovary syndrome (PCOS)
Metformin treatment of women with PCOS has been shown to improve ovarian function, reduce hyperandrogenicity and induce weight loss. The aim of this prospective study was to investigate the nature of the weight loss in obese women with PCOS, using 2 dose regimes.. Methods: Obese (body mass index [BMI] , 29 kilograms /m2) women with PCOS (n = 44) were recruited to the study, and randomised to receive either 1500mg metformin daily (n = 22), or 2550mg metformin daily (n = 22). Inclusion criteria were obesity (BMI,29), associated with 2 of: oligomenorrhoea, raised free androgen index (FAI, ,7), or ultrasound evidence of polycystic ovaries. They were assessed for anthropometric data, ovarian volume, circulating reproductive hormones, glycaemic and lipid parameters prior to starting treatment, and after 8 months.. Results: Significant reductions in weight were recorded on both doses of metformin at 8 months. The 1500mg group lost 3.3 Kg, representing a reduction in mean BMI from 38.4 to 37.3, while ...
Laparoscopic Ovarian Drilling (Ovarian Diathermy) for PCOS | UW Health | Madison, WILaparoscopic Ovarian Drilling (Ovarian Diathermy) for PCOS | UW Health | Madison, WI
Laparoscopic ovarian drilling is a surgical treatment that can trigger ovulation in women who have polycystic ovary syndrome (PCOS). Electrocautery or a laser is used to destroy parts of the ovaries.. This surgery is not commonly used. But it can be an option for women who are still not ovulating after losing weight and trying fertility medicines.. Ovarian drilling is usually done through a small incision (laparoscopy), with general anesthesia. The surgeon makes a small cut (incision) in the abdomen at the belly button. The surgeon then places a tube to inflate the abdomen with a small amount of carbon dioxide gas so that he or she can insert the viewing instrument (laparoscope) without damage to the internal organs. The surgeon looks through the laparoscope at the internal organs. Surgical instruments may be inserted through the same incision or other small incisions in the pelvic area.. Because the incisions are so small, laparoscopy is often called "Band-Aid surgery.". ...
Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism | AVESİSNon polycystic ovary syndrome-related endocrine disorders associated with hirsutism | AVESİS
Background Hyperandrogenism refers to classical androgen-dependent signs such as hirsutism, acne and androgenetic alopecia. Hirsutism is the main hyperandrogenic symptom, defined as an excess of body hair in the androgen-sensitive skin regions of the women. In this review, we attempt to focus on the pathogenesis of hirsutism related to disorders other than polycystic ovary syndrome (PCOS). Also, we will discuss their clinical and biochemical features as well as therapeutic options. Design Several original articles, meta-analysis and reviews have been screened in the field of hirsutism and hyperandrogenic disorders. Results Current English literature including our studies suggests that PCOS is the most common cause of hirsutism. The most important purpose for investigation is to identify those women with androgen-secreting tumours because of their life-threatening potential. In approximately 18% of the women with hirsutism, the underlying cause is nonclassical adrenal hyperplasia because of ...
Conditions and Diseases: Endocrine Disorders: Gonads: Polycystic Ovarian Syndrome, directory for Conditions and Diseases...Conditions and Diseases: Endocrine Disorders: Gonads: Polycystic Ovarian Syndrome, directory for Conditions and Diseases...
Conditions and Diseases: Endocrine Disorders: Gonads: Polycystic Ovarian Syndrome, all about Conditions and Diseases/Endocrine Disorders/Gonads/Polycystic Ovarian Syndrome
Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome | Clinical Research Trial Listing (...Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome | Clinical Research Trial Listing (...
New life-saving treatments for Polycystic ovary syndrome in clinical trial on Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
난임치료난임치료
Women with valid ovary function but oligomenorrhea due to the malfunction of the subthalamus - pituitary gland axis can properly induce ovulation through the administration of gonadotrophin. Women with valid subthalamus - pituitary gland - ovarian function but oligomenorrheic due to discordance of mutual organic balance of the axis can induce ovulation through injecting clomiphen, gonadotrophin and others. Obese women with high serum insulin concentration can induce ovulation through diet and hypoglycemic agent. A typical case is the polycystic ovary syndrome women; Induction of ovulation is archived through diet, hypoglycemic agent, clomiphen, gonadotrophin, etc. In other cases, oligomenorrheic women due to hyperprolactinemia can induce ovulation with dopamine and oligomenorrheic women due to thyroidal disease can induce ovulation through effective controlling of thyroid hormone. It helps to maintain a well-regulated life and stop smoking, limit liquor, maintain your weight, prevent stress in ...
Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome - Minerva Ginecologica 2014...Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome - Minerva Ginecologica 2014...
METHODS: A total of 60 women with PCOS and infertility were evaluated. Inclusions criteria were: age 26-34 years, nulliparity, above 3 years of sterility, multiple ovarian microcysts, BMI>27.5, oligomenorrhea/amenorrhea, hyperandrogenism and normal male fertility. Four patients were excluded (renal damage 2, tubal occlusion 1 and Pelvic Inflammatory Disease 1). The remaining 56 were divided into 2 groups: group A were inducted with Clomiphene Citrate alone, while group B were inducted with Clomiphene citrate and Metformin ...
Polycystic ovarian syndrome: N-acetyl-cysteine is a novel adjuvant to clomipbene citrate in clomiphene citrate-resistant...Polycystic ovarian syndrome: N-acetyl-cysteine is a novel adjuvant to clomipbene citrate in clomiphene citrate-resistant...
Polycystic ovarian syndrome: N-acetyl-cysteine is a novel adjuvant to clomipbene citrate in clomiphene citrate-resistant patients. Health and Medicine Reference Covering Thousands of Diseases and Prescription Drugs.
CO-EXISTENCE OF PCOS AND HYPOTHYROIDISM - Furocyst - For Management of PCOSCO-EXISTENCE OF PCOS AND HYPOTHYROIDISM - Furocyst - For Management of PCOS
is one such condition which is affected highly by the imbalance of hormones. Testosterone is one of those hormones. Increase in testosterones (male hormone) inside females causes the reproductive system to become infertile along with the development of multiple cysts in the ovaries. This worsens the condition of PCOS.. Thus, hypothyroidism gives rise to PCOS inside females. It has been seen that thyroid disorders and polycystic ovary syndrome (PCOS) are two of the most common endocrine disorders in the general population.. WHAT COULD BE THE REASON BEHIND DEVELOPMENT OF PCOS DUE TO HYPOTHYROIDISM?. One reason has been given that increase in testosterone levels causes PCOS in hypothyroid-affecting females.. Another reason is the rise in thyrotropin-releasing hormone (TRH). Rise in thyrotropin-releasing hormone (TRH) in primary hypothyroidism leads to increased prolactin and thyroid stimulating hormone (TSH). Prolactin contributes toward polycystic ovarian syndrome by inhibiting ovulation as a ...
Polycystic Ovarian Syndrome (PCOS) Treatment - Natural PCOS Treatment | Calgary - Nielsen Clinic - Homeopathy | Acupuncture |...Polycystic Ovarian Syndrome (PCOS) Treatment - Natural PCOS Treatment | Calgary - Nielsen Clinic - Homeopathy | Acupuncture |...
Natural Treatments for Polycystic Ovarian Syndrome (PCOS) Helping those who experience Polycystic Ovarian Syndrome (PCOS) by treating the root cause.
The impact of self-reported oligo-amenorrhea and hirsutism on fertility and lifetime reproductive success: results from the...The impact of self-reported oligo-amenorrhea and hirsutism on fertility and lifetime reproductive success: results from the...
STUDY QUESTION: To what extent do self-reported oligo-amenorrhea and hirsutism affect reproductive performance (childlessness, age at first delivery, family size and miscarriage rates)?. SUMMARY ANSWER: At the age of 44, among women with both self-reported oligo-amenorrhea and hirsutism the prevalence of childlessness was not significantly different from non-symptomatic women but they had a smaller family size than non-symptomatic women.. WHAT IS KNOWN ALREADY: Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by oligo-amenorrhea or amenorrhea, hyperandrogenism and hirsutism and it is the most frequent cause of anovulatory infertility, but there are few studies on the reproductive capacity of women with PCOS. In our previous population-based cohort study the women with self-reported oligo-amenorrhea and hirsutism were found to have more infertility problems and smaller family size than non-symptomatic women at the age of 31.. STUDY DESIGN, SIZE, DURATION: A ...
Women Health: Dietary composition in the treatment of polycystic ovary syndromeWomen Health: Dietary composition in the treatment of polycystic ovary syndrome
In the study to to compare the effect of different diet compositions on anthropometric, reproductive, metabolic, and psychological outcomes in PCOS of a total of 4,154 articles were retrieved and six articles from five studies met the a priori selection criteria, with 137 women included, posted in PubMed, showed that there were subtle differences between diets, with greater weight loss for a monounsaturated fat-enriched diet; improved menstrual regularity for a low-glycemic index diet; increased free androgen index for a high-carbohydrate diet; greater reductions in insulin resistance, fibrinogen, total, and high-density lipoprotein cholesterol for a low-carbohydrate or low-glycemic index diet; improved quality of life for a low-glycemic index diet; and improved depression and self-esteem for a high-protein diet. Weight loss improved the presentation of PCOS regardless of dietary composition in the majority of studies. Weight loss should be targeted in all overweight women with PCOS through ...
POLYCYSTIC OVARY SYNDROME & HOMEOPATHY - punehomeopathyPOLYCYSTIC OVARY SYNDROME & HOMEOPATHY - punehomeopathy
PCOS is a disease of the endocrine, that is, hormonal system of the body, affecting an ever increasing number of females, from 11 to 45 yrs age group. Presently PCOS is a major cause of Infertility. PCO and PCOS are two different entities, the former refers to Ovaries being enlarged with trapped…
Primary infertility: characteristics of women in North America according to pathological findings. - Oxford Cancer Epidemiology...Primary infertility: characteristics of women in North America according to pathological findings. - Oxford Cancer Epidemiology...
STUDY OBJECTIVE: To determine, in women with primary infertility, whether specific characteristics or behavioural factors are associated with the various pathological conditions identified as contributing to the infertility. DESIGN: Case-control study. SETTING: Seven institutions in the USA or Canada. PARTICIPANTS: Study subjects were 1750 women who presented with primary infertility, among whom the main pathological cause of infertility was male factor (417), tubal obstruction (231), endometriosis (194), luteal phase defects (153), other ovulatory problems (193), cervical abnormalities (92), and polycystic ovarian disease (84) and 1765 control women who delivered their first child at the same institution. MAIN RESULTS: Except for tubal obstruction and polycystic ovarian disease, the characteristics and behaviours of the women with infertility did not differ appreciably according to the pathological conditions recorded. Women with tubal obstruction had had more sexual partners, an earlier age at first
Polycystic Ovary Syndrome (PCOS) - About Women by WomenPolycystic Ovary Syndrome (PCOS) - About Women by Women
About Women by Women provides treatment for PCOS in Wellesley, MA and the greater Boston area. Learn more about PCOS and book your appointment today!
Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)
This study is a prospective randomized clinical trial to compare the endocrine and metabolic effects of two anti diabetic drugs (metformin vs. acarbose)
Inositol with Folic Acid - AiwoInositol with Folic Acid - Aiwo
Myo-inositol Rather Than D-chiro-inositol Is Able To Improve Oocyte Quality In Intracytoplasmic Sperm Injection Cycles. A Prospective, Controlled, Randomized Trial. http://www.ncbi.nlm.nih.gov/pubmed/21608442. The Combined Therapy With Myo-inositol And D-chiro-inositol Reduces The Risk Of Metabolic Disease In PCOS Overweight Patients Compared To Myo-inositol Supplementation Alone. http://www.ncbi.nlm.nih.gov/pubmed/22774396. Effects Of Inositol On Ovarian Function And Metabolic Factors In Women With PCOS: A Randomized Double Blind Placebo-controlled Trial. http://www.ncbi.nlm.nih.gov/pubmed/15206484. Effects Of D-chiro-inositol In Lean Women With The Polycystic Ovary Syndrome. http://www.ncbi.nlm.nih.gov/pubmed/15251831. Efficacy Of Myo-inositol In The Treatment Of Cutaneous Disorders In Young Women With Polycystic Ovary Syndrome. http://www.ncbi.nlm.nih.gov/pubmed/19551544. ...
Polycystic Ovary Syndrome (PCOS) - Infertility TreatmentPolycystic Ovary Syndrome (PCOS) - Infertility Treatment
Learn how Traditional Chinese Medicine (TCM), Acupuncture, & Naturopathic medicine can help you overcome PCOS, restore hormonal balance, get pregnant, and create the happy healthy family you desire. Setup a free consultation with one of our reproductive health experts. Locations in Vancouver, Surrey, & Kelowna.
Polycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet? | Diabetes SpectrumPolycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet? | Diabetes Spectrum
While studying effects of parathyroidectomy, it was discovered that guanide derivatives had hypoglycemic actions.11 The initial guanides were toxic. Metformin, a biguanide, is an antihyperglycemic agent that improves glucose intolerance. In patients with type 2 diabetes, it lowers both basal and postprandial plasma glucose concentrations. Its pharmacological mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.. The liver does not metabolize metformin. Renal excretion is the primary mode of clearance from the body. It is contraindicated in patients with significant renal dysfunction. The most significant risk associated with metformin is that of lactic acidosis. Although lactic acidosis is associated with 50% mortality, it is exceedingly rare in subjects with normal renal function. ...
MetforminMetformin
Diabetes mellitus type 2Diabetes mellitus type 2
AntiandrogenAntiandrogen
Gestational diabetesGestational diabetes
1D-chiro-Inositol1D-chiro-Inositol
FlutamideFlutamide
Hormonal contraceptionHormonal contraception
AnovulationAnovulation
GonadoblastomaGonadoblastoma
MiscarriageMiscarriage
LuteomaLuteoma
Seborrhoeic dermatitisSeborrhoeic dermatitis
Obesity and fertilityObesity and fertility
ClomifeneClomifene
Ovarian drillingOvarian drilling
AcneAcne
Helen Mason (endocrinologist)Helen Mason (endocrinologist)
ValproateValproate
CiticolineCiticoline
Congenital generalized lipodystrophyCongenital generalized lipodystrophy
Alka KriplaniAlka Kriplani
Eating disorderEating disorder
多囊卵巢綜合症 - 维基百科，自由的百多囊卵巢綜合症 - 维基百科，自由的百
Seborrhoeic dermatitisSeborrhoeic dermatitis
Seborrhoeic dermatitisSeborrhoeic dermatitis
High-grade serous carcinomaHigh-grade serous carcinoma
Ricardo AzzizRicardo Azziz
Miscarriage risksMiscarriage risks
FollistatinFollistatin
Type 2 diabetesType 2 diabetes
Cushings diseaseCushing's disease
Familial partial lipodystrophyFamilial partial lipodystrophy
Short statureShort stature
AntiandrogenAntiandrogen
நீரிழிவு நோய் (இரண்டாவது வகை) - தமிழ் விக்கிப்பீடியாநீரிழிவு நோய் (இரண்டாவது வகை) - தமிழ் விக்கிப்பீடியா
Beta polipeptid luteinizirajućeg hormonaBeta polipeptid luteinizirajućeg hormona
Kidney diseaseKidney disease
ClitoromegalyClitoromegaly
ಗರ್ಭಪಾತ - ವಿಕಿಪೀಡಿಯಗರ್ಭಪಾತ - ವಿಕಿಪೀಡಿಯ
Breast atrophyBreast atrophy
Anorexia nervosaAnorexia nervosa
Ակնե - Վիքիպեդիա՝ ազատ հանրագիտարանԱկնե - Վիքիպեդիա՝ ազատ հանրագիտարան
Diabetes insipidusDiabetes insipidus
13-Hydroxyoctadecadienoic acid13-Hydroxyoctadecadienoic acid
Luteinizing hormoneLuteinizing hormone
위키백과:미번역 문서/의학 - 위키백과, 우리 모두의 백과사전위키백과:미번역 문서/의학 - 위키백과, 우리 모두의 백과사전
Diabetic nephropathyDiabetic nephropathy
Diabetes mellitus type 1Diabetes mellitus type 1
Vaginal bleedingVaginal bleeding
Pituitary apoplexyPituitary apoplexy
Primordial dwarfismPrimordial dwarfism
Diabetes mellitus type 1Diabetes mellitus type 1
RamadanRamadan
Sindrom ovarium polikistik bahasa Indonesia, ensiklopedia bebasSindrom ovarium polikistik bahasa Indonesia, ensiklopedia bebas
Deshidroepiandrosterona, a enciclopedia libreDeshidroepiandrosterona, a enciclopedia libre
Hypothalamic-pituitary-gonadal axisHypothalamic-pituitary-gonadal axis
BleedingBleeding
AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Polycystic Ovary SyndromeHyperandrogenismHirsutismOvaryOligomenorrheaMetforminAnovulationClomiphenePolycystic Kidney DiseasesInsulin ResistanceTestosteroneAndrogensInfertility, FemaleFertility Agents, FemaleSyndrome17-alpha-HydroxyprogesteroneAndrostenedioneMenstruation DisturbancesPolycystic Kidney, Autosomal DominantLuteinizing HormoneDehydroepiandrosterone SulfateOvulation InductionCyproterone AcetateSex Hormone-Binding GlobulinAcne VulgarisFollicle Stimulating HormoneAnti-Mullerian HormoneHypoglycemic AgentsInsulinOvulationBody Mass IndexObesityMenstrual CycleCase-Control StudiesPregnancyAmenorrheaBlood GlucoseElectrocoagulationGlucose Tolerance TestHyperinsulinismEthinyl EstradiolHormonesOvarian FollicleMetabolic Syndrome XGonadotropinsDiathermyPregnancy RateMenstruationSteroid 17-alpha-HydroxylaseVirilismDehydroepiandrosteroneFollicle Stimulating Hormone, HumanTRPP Cation ChannelsPolycystic Kidney, Autosomal RecessiveGonadal Steroid HormonesLive BirthMenstruation-Inducing AgentsTheca CellsOvarian Hyperstimulation SyndromeEstradiolFertilization in VitroOvarian DiseasesAcanthosis NigricansReproductive Techniques, AssistedAdrenarcheFollicular FluidSteroidsThiazolidinedionesGonadotropin-Releasing HormoneTestosterone PropionateInfertilityFollistatinElectroacupunctureGlucose IntoleranceReceptors, FSHPhenotypeWaist-Hip RatioBiological MarkersRisk FactorsPrevalenceOverweightProgesteroneDiabetes, GestationalGlucose Metabolism DisordersProspective StudiesAndrogen AntagonistsGenotypeAdiponectinThinnessEndocrine System DiseasesAlopeciaNational Institute of Child Health and Human Development (U.S.)CystsHair RemovalFollicular PhaseContraceptives, Oral, CombinedContraceptive AgentsPolymorphism, Single NucleotideChorionic GonadotropinPregnancy OutcomeInhibinsGranulosa CellsCohort StudiesGene FrequencyBody ConstitutionCross-Sectional StudiesAbdominal FatDown SyndromeGlucose Clamp TechniqueHormones, EctopicPolymorphism, GeneticTreatment OutcomeGenetic Predisposition to DiseaseLipidsReference Values
Polycystic ovary syndrome: MedlinePlus GeneticsPolycystic ovary syndrome: MedlinePlus Genetics
How to Get Pregnant With Polycystic Ovary Syndrome (PCOS)How to Get Pregnant With Polycystic Ovary Syndrome (PCOS)
polycystic ovary syndrome Disease Ontology Browser - DOID:11612polycystic ovary syndrome Disease Ontology Browser - DOID:11612
Polycystic ovary syndrome - Simple English Wikipedia, the free encyclopediaPolycystic ovary syndrome - Simple English Wikipedia, the free encyclopedia
Infertility in polycystic ovary syndrome - WikipediaInfertility in polycystic ovary syndrome - Wikipedia
Polycystic Ovary Syndrome PCOS | Endocrine SocietyPolycystic Ovary Syndrome PCOS | Endocrine Society
Polycystic Ovary Syndrome - Lets Talk HealthPolycystic Ovary Syndrome - Let's Talk Health
Women with Polycystic Ovary Syndrome Have Less Bacterial Diversity in GutWomen with Polycystic Ovary Syndrome Have Less Bacterial Diversity in Gut
Polycystic Ovary Syndrome Journals | OMICS Group | Gynecology And ObstetricsPolycystic Ovary Syndrome Journals | OMICS Group | Gynecology And Obstetrics
Effects of Exercise Intervention on the Improvement of Polycystic Ovary Syndrome | IntechOpenEffects of Exercise Intervention on the Improvement of Polycystic Ovary Syndrome | IntechOpen
Polycystic Ovary Syndrome (PCOS)Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome | Archives of Disease in ChildhoodPolycystic ovary syndrome | Archives of Disease in Childhood
Polycystic ovary syndrome/Disease (PCOS or PCOD) SymptomsPolycystic ovary syndrome/Disease (PCOS or PCOD) Symptoms
Current trends in the treatment of polycystic ovary syndrome with desi | TCRMCurrent trends in the treatment of polycystic ovary syndrome with desi | TCRM
PCOS (Polycystic Ovary Syndrome) and Diabetes | CDCPCOS (Polycystic Ovary Syndrome) and Diabetes | CDC
Polycystic Ovary SyndromePolycystic Ovary Syndrome
polycystic ovary syndromepolycystic ovary syndrome
Polycystic Ovary SyndromePolycystic Ovary Syndrome
Polycystic ovary syndrome - Symptoms - NHSPolycystic ovary syndrome - Symptoms - NHS
PCOS | Polycystic Ovary Syndrome | MedlinePlusPCOS | Polycystic Ovary Syndrome | MedlinePlus
Polycystic Ovary Syndrome | Encyclopedia.comPolycystic Ovary Syndrome | Encyclopedia.com
Polycystic ovary syndromePolycystic ovary syndrome
Polycystic Ovary Syndrome DiagnosisPolycystic Ovary Syndrome Diagnosis
Polycystic Ovary Syndrome TreatmentPolycystic Ovary Syndrome Treatment
1st Gene Linked to Polycystic Ovary Syndrome1st Gene Linked to Polycystic Ovary Syndrome
Can polycystic ovary syndrome (PCOS) be cured?Can polycystic ovary syndrome (PCOS) be cured?
Shining a light on polycystic ovary syndromeShining a light on polycystic ovary syndrome
What Is Polycystic Ovary Syndrome?What Is Polycystic Ovary Syndrome?
Polycystic Ovary SyndromePolycystic Ovary Syndrome
Polycystic Ovary SyndromePolycystic Ovary Syndrome
Polycystic ovary syndrome: Womans shock endometrial cancer diagnosisPolycystic ovary syndrome: Woman's shock endometrial cancer diagnosis
Diagnosis and Management of Polycystic Ovary Syndrome | SpringerLinkDiagnosis and Management of Polycystic Ovary Syndrome | SpringerLink
Cause of polycystic ovary syndrome discovered at last | New ScientistCause of polycystic ovary syndrome discovered at last | New Scientist
Cause of polycystic ovary syndrome discovered at last | New ScientistCause of polycystic ovary syndrome discovered at last | New Scientist
Polycystic Ovary Syndrome (PCOS)Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome | NursingPolycystic Ovary Syndrome | Nursing
Polycystic Ovary Syndrome (PCOS)Polycystic Ovary Syndrome (PCOS)
Why Doctors Dont Understand Polycystic Ovary Syndrome - The AtlanticWhy Doctors Don't Understand Polycystic Ovary Syndrome - The Atlantic
Polycystic ovary syndrome and fertility: Causes, symptoms, and effectsPolycystic ovary syndrome and fertility: Causes, symptoms, and effects
3 Ways to Manage Polycystic Ovary Syndrome (PCOS) - wikiHow3 Ways to Manage Polycystic Ovary Syndrome (PCOS) - wikiHow
Polycystic Ovary Syndrome: 5 Things You Might Not KnowPolycystic Ovary Syndrome: 5 Things You Might Not Know
Polycystic ovary syndrome - WikipediaPolycystic ovary syndrome - Wikipedia
Polycystic Ovary Syndrome Puts Glucose Control In Double Jeopardy - RedorbitPolycystic Ovary Syndrome Puts Glucose Control In Double Jeopardy - Redorbit
AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Polycystic Ovary SyndromeHyperandrogenismHirsutismOvaryOligomenorrheaMetforminAnovulationClomiphenePolycystic Kidney DiseasesInsulin ResistanceTestosteroneAndrogensInfertility, FemaleFertility Agents, FemaleSyndrome17-alpha-HydroxyprogesteroneAndrostenedioneMenstruation DisturbancesPolycystic Kidney, Autosomal DominantLuteinizing HormoneDehydroepiandrosterone SulfateOvulation InductionCyproterone AcetateSex Hormone-Binding GlobulinAcne VulgarisFollicle Stimulating HormoneAnti-Mullerian HormoneHypoglycemic AgentsInsulinOvulationBody Mass IndexObesityMenstrual CycleCase-Control StudiesPregnancyAmenorrheaBlood GlucoseElectrocoagulationGlucose Tolerance TestHyperinsulinismEthinyl EstradiolHormonesOvarian FollicleMetabolic Syndrome XGonadotropinsDiathermyPregnancy RateMenstruationSteroid 17-alpha-HydroxylaseVirilismDehydroepiandrosteroneFollicle Stimulating Hormone, HumanTRPP Cation ChannelsPolycystic Kidney, Autosomal RecessiveGonadal Steroid HormonesLive BirthMenstruation-Inducing AgentsTheca CellsOvarian Hyperstimulation SyndromeEstradiolFertilization in VitroOvarian DiseasesAcanthosis NigricansReproductive Techniques, AssistedAdrenarcheFollicular FluidSteroidsThiazolidinedionesGonadotropin-Releasing HormoneTestosterone PropionateInfertilityFollistatinElectroacupunctureGlucose IntoleranceReceptors, FSHPhenotypeWaist-Hip RatioBiological MarkersRisk FactorsPrevalenceOverweightProgesteroneDiabetes, GestationalGlucose Metabolism DisordersProspective StudiesAndrogen AntagonistsGenotypeAdiponectinThinnessEndocrine System DiseasesAlopeciaNational Institute of Child Health and Human Development (U.S.)CystsHair RemovalFollicular PhaseContraceptives, Oral, CombinedContraceptive AgentsPolymorphism, Single NucleotideChorionic GonadotropinPregnancy OutcomeInhibinsGranulosa CellsCohort StudiesGene FrequencyBody ConstitutionCross-Sectional StudiesAbdominal FatDown SyndromeGlucose Clamp TechniqueHormones, EctopicPolymorphism, GeneticTreatment OutcomeGenetic Predisposition to DiseaseLipidsReference Values
PCOSCalled hyperandrogenismUltrasoundOvulationSymptomsInfertilityManagement of Polycystic Ovary SyFolliclesAffectsHirsutismCondition called polycystic ovary syObesityRisk of developing polycystEndocrineInsulinImbalanceHormones2016PrevalencePeriodsAndrogensMetabolic syndromeOvarian SyndromeInsulinHirsutismANOVULATIONPatients with polycystic ovary syDiagnosisMultiple cystsCauses Polycystic Ovary SyAMENORRHEAExcessReproductiveDisorderTreatment of polycystic ovary sySmall cystsStein LeventhaTreat polycystic ovary syDiagnose polycystic ovary syIrregular periodsHormone2018ClinicalFollicles in the ovariesGeneticsPresence of polycystic ovariesDiabetesObesitySymptoms of polycysticWoman'sUltrasound examinationMenstrual cyclePelvicPituitary gland
PCOS55
Called hyperandrogenism2
Ultrasound3
Ovulation6
Symptoms4
Infertility2
Management of Polycystic Ovary Sy2
  • In Current Management of Polycystic Ovary Syndrome (pp. 173-184). (elsevier.com)
  • The National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Polycystic Ovary Syndrome (CREPCOS) has released the updated evidence-based guideline for the assessment and management of polycystic ovary syndrome for public consultation. (edu.au)
Follicles11
Affects5
Hirsutism1
  • The elevated level of male hormones, also known as ovarian androgen excess, from the ovary (and sometimes from the adrenal gland as well) causes male-pattern hair growth (hirsutism) on the upper lip, chin, neck, sideburn area, chest, upper or lower abdomen and inner thigh. (familyfertility.com)
Condition called polycystic ovary sy1
  • In some instances, the ovaries produce larger quantities of these chemicals, leading to a condition called polycystic ovary syndrome. (gynecology-doctors.com)
Obesity1
Risk of developing polycyst2
  • Common variations (polymorphisms) in several genes have been associated with the risk of developing polycystic ovary syndrome. (medlineplus.gov)
  • Genetic variations likely act in combination with health and lifestyle factors to influence a woman's overall risk of developing polycystic ovary syndrome. (medlineplus.gov)
Endocrine1
Insulin2
  • Other genes associated with polycystic ovary syndrome are involved in energy production, immune system responses to injury (inflammation), insulin production and regulation, and pathways involved in the production of fats. (medlineplus.gov)
  • Legro, RS 2002, ' Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome ', Journal of Pediatric Endocrinology and Metabolism , vol. 15, no. (elsevier.com)
Imbalance1
Hormones5
20161
  • https://www.r-health.md/wp-content/uploads/Blog-POS.png 315 560 James Bancroft https://www.r-health.md/wp-content/uploads/2016/03/RHE_logo.png James Bancroft 2019-08-07 13:31:15 2019-05-28 15:33:14 ARE YOU SUFFERING FROM POLYCYSTIC OVARY SYNDROME? (r-health.md)
Prevalence1
Periods1
Androgens1
Metabolic syndrome3
Ovarian Syndrome8
Insulin33
Hirsutism6
ANOVULATION3
Patients with polycystic ovary sy3
  • N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. (empowher.com)
  • Effects of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome--a randomized placebo-controlled trial. (empowher.com)
  • Acupuncture at Zhibian through Shuidao could significantly improve the basic temperature of patients with polycystic ovary syndrome, and regulate hormone level of reproductive endocrine. (greenmedinfo.com)
Diagnosis6
Multiple cysts6
Causes Polycystic Ovary Sy1
AMENORRHEA2
Excess4
  • Now, Paolo Giacobini at the French National Institute of Health and Medical Research and his colleagues have found that the syndrome may be triggered before birth by excess exposure in the womb to a hormone called anti-Müllerian hormone. (newscientist.com)
  • She didn't initially show any of the physical symptoms, like excess hair growth, cystic acne, or obesity, but a blood test revealed that she had high levels of testosterone and an ultrasound showed cysts on her ovaries. (theatlantic.com)
  • Polycystic ovary syndrome, a condition affecting about 10 percent of women and characterized by excess male hormone and increased risk of diabetes and heart disease, appears to cause a sort of double jeopardy for those struggling the hardest to control blood sugar levels, researchers report. (redorbit.com)
  • Polycystic ovary syndrome is a disorder involving infrequent, irregular or prolonged menstrual periods, and often excess male hormone (androgen) levels. (mayoclinic.org)
Reproductive5
Disorder4
Treatment of polycystic ovary sy2
  • Almost 89% of the molecules that are being investigated for the treatment of polycystic ovary syndrome are small molecule. (benzinga.com)
  • See 'Treatment of polycystic ovary syndrome in adolescents' . (uptodate.com)
Small cysts4
Stein Leventha1
Treat polycystic ovary sy1
  • The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat polycystic ovary syndrome. (benzinga.com)
Diagnose polycystic ovary sy1
Irregular periods1
  • If you have irregular periods and/or you're struggling to conceive , see your GP, who will do a blood test to measure your hormone levels and may order an ultrasound test to look at your ovaries and check for cysts. (bounty.com)
Hormone9
20181
Clinical3
Follicles in the ovaries1
Genetics2
Presence of polycystic ovaries1
Diabetes4
  • By age 40, about 10 percent of overweight women with polycystic ovary syndrome develop abnormally high blood sugar levels ( type 2 diabetes ), and up to 35 percent develop prediabetes (higher-than-normal blood sugar levels that do not reach the cutoff for diabetes). (medlineplus.gov)
  • Helena J. Teede, MD, Director Monash Centre for Health Research and Implementation, Melbourne, Victoria, Australia, made a case for renaming polycystic ovary syndrome at the 76th Scientific Sessions of the American Diabetes Association, June 10-14, in New Orleans. (endocrineweb.com)
  • The former condition has an established link with long-term macrovascular diseases such as type 2 diabetes mellitus, hypertension, and atherosclerotic heart disease, consequences that also are observed in women with polycystic ovary syndrome. (aafp.org)
  • Long Term Sequelae of Polycystic Ovary Syndrome: Diabetes and Cardiovascular Disease 9. (routledge.com)
Obesity2
  • We are seeing an explosion in polycystic ovary syndrome in adolescent girls, and I think it's due to the fact that we are also seeing an explosion in obesity in adolescent girls," Nestler said. (theatlantic.com)
  • Hyperandrogenism is exacerbated by obesity and is a key feature of polycystic ovary syndrome. (endocrineweb.com)
Symptoms of polycystic1
Woman's1
  • Genetic variations likely act in combination with health and lifestyle factors to influence a woman's overall risk of developing polycystic ovary syndrome. (medlineplus.gov)
Ultrasound examination1
Menstrual cycle2
Pelvic4
Pituitary gland2
Polycystic Ovary Syndrome Weight Loss - Losing Weight With PCOS
Polycystic Ovary Syndrome Weight Loss - Losing Weight With PCOS (theweighwewere.com)
Polycystic Ovary Syndrome Diagnosis
Polycystic Ovary Syndrome Diagnosis (news-medical.net)
How to Get Pregnant With Polycystic Ovary Syndrome (PCOS)
How to Get Pregnant With Polycystic Ovary Syndrome (PCOS) (wikihow.com)
Polycystic Ovary Syndrome | GreenMedInfo | Disease | Natural Medicine
Polycystic Ovary Syndrome | GreenMedInfo | Disease | Natural Medicine (greenmedinfo.com)
Introduction to Polycystic ovarian syndrome (PCOS) | gıdalar | Polycystic ovary syndrome, Causes of female infertility,...
Introduction to Polycystic ovarian syndrome (PCOS) | gıdalar | Polycystic ovary syndrome, Causes of female infertility,... (pinterest.com)
Https://www.medicalnewstoday.com/articles/314215.php
Https://www.medicalnewstoday.com/articles/314215.php (medicalnewstoday.com)
Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (kidshealth.org)
10 Metabolism Boosting Facts and Myths
10 Metabolism Boosting Facts and Myths (medicinenet.com)
SUOX gene: MedlinePlus Genetics
SUOX gene: MedlinePlus Genetics (medlineplus.gov)
Organizations by topic beginning with P: MedlinePlus
Organizations by topic beginning with P: MedlinePlus (medlineplus.gov)
What are normal testosterone levels? Ages, males, females, and more
What are normal testosterone levels? Ages, males, females, and more (medicalnewstoday.com)
Dense mapping of the region of insulin gene VNTR in polycystic ovary syndrome in a population of women from Central Europe |...
Dense mapping of the region of insulin gene VNTR in polycystic ovary syndrome in a population of women from Central Europe |... (journals.viamedica.pl)
Polycystic Ovary Syndrome (PCOS) Care
Polycystic Ovary Syndrome (PCOS) Care (pcoscareindia.com)
Symptoms of rheumatoid arthritis (RA) in women
Symptoms of rheumatoid arthritis (RA) in women (medicalnewstoday.com)
Https://www.medicalnewstoday.com/articles/321929.php
Https://www.medicalnewstoday.com/articles/321929.php (medicalnewstoday.com)
PCOS (Polycystic Ovary Syndrome) and Diabetes | CDC
PCOS (Polycystic Ovary Syndrome) and Diabetes | CDC (cdc.gov)
Polycystic Ovary Syndrome: A Guide to Clinical Management, 1st Edition (Paperback) - Routledge
Polycystic Ovary Syndrome: A Guide to Clinical Management, 1st Edition (Paperback) - Routledge (routledge.com)
Metformin Hydrochloride Monograph for Professionals - Drugs.com
Metformin Hydrochloride Monograph for Professionals - Drugs.com (drugs.com)
Polycystic ovary syndrome
Polycystic ovary syndrome (netdoctor.co.uk)
Polycystic Ovary Syndrome | A Pipeline Analysis Report 2018 | Technavio | Benzinga
Polycystic Ovary Syndrome | A Pipeline Analysis Report 2018 | Technavio | Benzinga (benzinga.com)
Dark Knuckles: Causes, Treatments, and Natural Remedies
Dark Knuckles: Causes, Treatments, and Natural Remedies (healthline.com)
Polycystic Ovary Syndrome Support | Dr. Gretchen Kubacky
Polycystic Ovary Syndrome Support | Dr. Gretchen Kubacky (pcoswellness.com)
Polycystic ovary syndrome and fertility: Causes, symptoms, and effects
Polycystic ovary syndrome and fertility: Causes, symptoms, and effects (medicalnewstoday.com)
Polycystic ovary syndrome (PCOS) - Care at Mayo Clinic - Mayo Clinic
Polycystic ovary syndrome (PCOS) - Care at Mayo Clinic - Mayo Clinic (mayoclinic.org)
4: Polycystic ovary syndrome | The Medical Journal of Australia
4: Polycystic ovary syndrome | The Medical Journal of Australia (mja.com.au)
Androgen Excess Clinical Presentation: History, Physical, Causes
Androgen Excess Clinical Presentation: History, Physical, Causes (emedicine.medscape.com)
Surprising Reasons for Weight Gain
Surprising Reasons for Weight Gain (rxlist.com)
Polycystic Ovary Syndrome Treatment
Polycystic Ovary Syndrome Treatment (news-medical.net)
PCOS Challenge: The National Polycystic Ovary Syndrome Association
PCOS Challenge: The National Polycystic Ovary Syndrome Association (m.pcoschallenge.org)
The Role of Metformin in PCOS-Related Infertility
The Role of Metformin in PCOS-Related Infertility (medscape.com)
Diagnosis and Management of Polycystic Ovary Syndrome | SpringerLink
Diagnosis and Management of Polycystic Ovary Syndrome | SpringerLink (link.springer.com)